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Abstract 
Presbycusis, or age-related hearing loss, is one of the most common conditions 
impacting the aging population, characterized by progressive sensorineural 
hearing loss and impairment in speech discrimination capability. Current 
management is limited to auditory rehabilitation with the assistance of hearing 
aids or cochlear implants in advanced cases. There currently exists no effective 
treatments available for the prevention or attenuation of hearing loss in 
association with presbycusis. The purpose of this study was to evaluate the 
potential of a combination antioxidant therapy in the prevention and treatment of 
presbycusis. The objectives of this randomized controlled animal study were to:  
identify an anesthetic which would allow for repeated reliable longitudinal 
auditory brainstem response (ABR) testing in a mouse model, identify a 
combination antioxidant which targets multiple sites within the oxidative pathway 
and assess its ability to prevent age-related threshold shifts and to arrest further 
age-related threshold shifts in C57BL6 mice with documented age-related 
threshold shifts. Mice were randomized to one of three groups: an early 
treatment group, a late treatment group, or a control group. The treatment groups 
of mice were fed with a combination agent comprised 6 antioxidant agents. ABRs 
were performed comparing Avertin to ketamine/xylazine with no significant 
difference in test thresholds. ABR thresholds were recorded at baseline and 
every 3 months following initiation of treatment in the 3 randomized groups. 
Threshold shifts from baseline were decreased in the treatment groups when 
compared to the control group at all tested frequencies and time points. 
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Chapter 1. Introduction and Research Objectives 
 
Presbycusis (or age-related hearing loss) is a common condition affecting 
the aging population. According to the United States Census Bureau, the 
population age 65 and older will more than double between the years of 2012 
and 2060. In 2060, it is estimated that approximately 92 million Americans will be 
within this age range (United States Census Bureau, 2012). With the rapidly 
increasing aging population, presbycusis is becoming an increasingly important 
public health concern.  
Age-related hearing loss represents the sum of cumulative damage to the 
auditory system that progresses with aging. As such, its etiology is multifactorial 
including oxidative injury associated with aging, noise exposure, ototoxin 
exposure, environmental toxin exposures, otologic disease, and injury from 
systemic disease. Various histopathologic changes have been noted in 
association with presbycusis including diffuse cellular losses, evidence of 
oxidative injury within the cochlea and evidence of atrophy of vascular supply 
within the stria vascularis. The typical clinical presentation of presbycusis is one 
of high frequency sensorineural hearing loss. Difficulty with speech 
understanding in ambient conditions and tinnitus are also commonly associated. 
Preventive actions should be employed to thwart otologic insult throughout life. 
However, clinical management options are limited; they include environmental 
modifications, hearing assistive devices, hearing aids and cochlear implants of 
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which only cochlear implants typically are covered my health insurance providers 
in cases of severe sensorineural hearing loss. There are no medical therapies 
currently available for the prevention or treatment of age-related hearing loss. 
Given the lack of support provided by health insurance providers for hearing 
assistive devices and hearing aids as well as the increase in the absolute 
number and percentage of the geriatric population, identifying a low cost, non-
surgical therapy for the treatment or prevention of age-related hearing loss 
presents an opportunity to have a significant public impact and positively 
influence the lives of many individuals. This was the goal of this dissertation. 
The objective of this study was to explore the possibility of preventing and 
attenuating age-related hearing loss by administration of a combination 
antioxidant therapy which targets multiple sites within the oxidative pathway.  
Within the cochlea, oxidative damage caused by free-radicals and reactive 
oxidative species has been widely demonstrated to contribute to the 
development of age-related hearing loss. The consequence of such cumulative 
oxidative stress is depletion of glutathione, an endogenous antioxidant, in 
cochlear cells which results in lack of protection from oxidants, loss of cochlear 
outer hair cells, alterations in biophysiology in the cochlear lateral wall and 
diminution in high frequency hearing acuity. To study the potential for preventing 
oxidative damage in the cochlea as related to aging a combination antioxidant 
was developed. C57BL/6 mice were used as an animal model. It was 
hypothesized that a combination antioxidant could be developed for oral 
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administration which targets multiple sites within the oxidative pathway and is 
safe for oral consumption in C57BL/6 mice. It was further hypothesized that age-
related hearing loss would be slowed or arrested by the administration of a 
combination agents that prevent or reduce this oxidative damage. Longitudinal 
analysis was required for assessment of progression of hearing loss in the 
C57BL/6 mice. The following specific aims were designed to address these 
issues:  
 
Specific Aim 1. To validate 2,2,2 tribromoethanol as an anesthetic 
for mouse auditory brainstem response (ABR) testing using the 
C57BL/6 mouse model.   
To study the impact of the combination antioxidant, longitudinal analysis 
was required with ABR assessments performed on the mice at various time 
points following treatment. Preliminary investigation revealed a significant rate of 
mortality in C57BL/6 mice following administration of standard doses of ketamine 
and xylazine anesthesia for the procedure. This high rate of mortality complicated 
the ability to perform longitudinal analysis. An alternative anesthetic was sought 
to provide adequate anesthesia for a period of approximately 60 minutes to 
complete the ABR testing with a low associated rate of mortality. Avertin, or 2,2,2 
tribromoethanol was chosen as an alternative to ketamine and xylazine because 
of its low morbidity and mortality profile reported within the literature. We 
hypothesized that 2,2,2 tribromoethanol would effectively provide adequate 
anesthesia for repeated reliable longitudinal auditory brainstem response (ABR) 
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testing in a mouse model without impacting otophysiological response. To test 
this hypothesis, we measured ABRs from mice anesthetized with both 2,2,2 
tribromoethanol and ketamine/xylazine, respectively. 
 
Specific Aim 2. To study the effects of daily, oral administration of a 
combination antioxidant targeting multiple sites within the oxidative 
pathway on the prevention of the onset of age-related hearing loss. 
We hypothesized that administration of a combination antioxidant 
targeting multiple site within the oxidative pathway can prevent the onset of age-
related hearing loss in C57BL/6 mice. This was tested by performing longitudinal 
ABR analysis in C57BL/6 mice that received antioxidant therapy prior to onset of 
age-related threshold shifts.  
 
Specific Aim 3. To study the effects of daily, oral administration of a 
combination antioxidant targeting multiple sites within the oxidative 
pathway on the prevention of the progression of age-related 
hearing loss. 
We hypothesized that administration of a combination antioxidant 
targeting multiple site within the oxidative pathway can prevent the progression of 
age-related hearing loss in C57BL/6 mice. This was tested by performing 
longitudinal ABR analysis in C57BL/6 mice that received antioxidant therapy 
following onset of age-related threshold shifts.  
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Chapter 2: Background and Significance 
 
Presbycusis is one of the most common conditions affecting the aging 
population. Presbycusis, also commonly referred to as age-related hearing loss 
(ARHL), may be defined as progressive sensorineural hearing loss that occurs as 
a function of a variety of contributing factors accumulated throughout life within 
the geriatric population. The hearing loss associated with ARHL is 
characteristically high frequency with accompanying deficits in speech 
discrimination. The prevalence of age-related hearing loss increases with age. 
The etiology of age-related hearing loss is multifactorial with oxidative injury, 
noise exposure, heredity and otologic injury (i.e. ototoxins and otologic disease) 
representing major contributing factors. Presbycusis has a wide potential impact 
not only on the individual, but also on society as a whole making prevention, 
early diagnosis and treatment of critical importance in circumventing this potential 
problem. This chapter provides an overview of the current state of knowledge 
regarding etiology, diagnosis, treatment and prevention of age-related hearing 
loss. This chapter also reviews the relevant histopathology and pathophysiology 
as related to presbycusis. A review of the literature regarding cochlear oxidative 
injury associated with age-related hearing loss and previously attempted 
antioxidants in the prevention of age related hearing loss is provided. Finally, a 
description of the C57BL/6 mouse model of age-related hearing loss as well as a 
review of mouse anesthetic for research procedures is presented.  
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Section 2.1: Clinical Perspective and Public Health Impact of 
ARHL 
Definition of Presbycusis 
Presbycusis may be defined as any sum of conditions and exposures that 
lead to the development and progression of hearing loss with aging. Age-related 
hearing loss is characterized by high frequency sensorineural hearing loss that 
progressively increases with aging. Figure 1 depicts an audiogram characteristic 
of moderately advanced age-related hearing loss. As can be seen in Figure 1, 
individuals with age-related hearing loss tend to develop losses within the 
frequencies at and above 2000 Hz earlier in the course of disease. As such, 
individuals tend to experience difficulty with understanding the voiceless 
consonants of speech (i.e. c (k), ch (tʃ), f (f), k (k), p (p), s (s), sh (ʃ), t (t), th (θ)). For 
example, patients with presbycusis may experience difficulty discriminating the 
words “bash,” “bath,” “bat,” “back,” “batch,” and “bass”. Because of this, patients 
often experience difficulty with speech understanding particularly in ambient 
conditions. The complaints that patients present with regarding this speech 
discernment in noise is often seemingly out of proportion to the degree of hearing 
loss noted on traditional audiologic testing in quiet. In fact, older adults with 
normal hearing have been demonstrated to perform worse on speech 
discrimination tasks particularly in noise when compared to young normal 
hearing adults (Gordon-Salant et al. 2005; Humes & Dubno, 2009; aGordon-
Salant et al. 2010; bGordon-Salant et al. 2010). These findings are dramatically 
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increased with pure-tone shifts in age-related hearing loss (Gordon-Salant et al. 
2005; bGordon-Salant et al. 2010). This can lead to significant deficits in 
communication ability in social, recreational and professional situations 
precipitating a sense of angst and frustration. 
 
Epidemiology 
Presbycusis or age-related hearing loss is one of the most common 
conditions affecting the aging population. Within the United States, presbycusis is 
among the top three most common condition affecting the aging population 
(aFrisina et al. 2006; Yueh et al. 2003). It is the most common communication 
disorder affecting the geriatric population (aFrisina et al. 2006). Table 1 presents 
recently published prevalence rates for age-related hearing loss (Seidman 2000, 
Yueh et al., 2003; Parham et al. 2011; Mao et al. 2013). Within the United States, 
for individuals over the age of 65 years, the prevalence of age-related hearing 
loss ranges from 35% to 50%( Seidman 2000, Yueh et al., 2003; Parham et al. 
2011). By age 75 years, the prevalence increases to 40% to 65%. By age 80 
years, the prevalence increases to approximately 80%, and at 100 years, the 
prevalence approximates 90% (Seidman 2000, Yueh et al., 2003; Parham et al. 
2011; Mao et al. 2013).  Similar prevalence rates have been reported 
internationally.   
In a review of 42 population-based studies in 2012, the World Health 
Organization (WHO) released estimates of disabling hearing loss rates in 
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individuals over the age of 65. The WHO defined disabling hearing loss as 
hearing loss greater than 40 dB in the better hearing ear (WHO, 2012). The 
estimated prevalence of disabling hearing loss in individuals age 64 years and 
older by international region is presented in Figure 2. With the exception of the 
Middle East and North Africa regions, all estimated prevalence rates fall between 
30% and 50% for individuals 65 years of age and over. The highest prevalence 
rates for disabling hearing loss in adults over 65 according to this review were 
noted in South Asia. Interestingly on review of United States prevalence alone, 
racial differences in prevalence have been reported (bLin et al., 2011). When 
comparing individuals who classify themselves as black and white, statistically 
significant differences in the rates of hearing loss defines as pure tone average in 
speech frequencies of greater than 25 dB in the better hearing ear were noted. 
Overall prevalence of hearing loss in black males age 70 and older was noted as 
48.3% (95% confidence interval: 36.3-60.3) versus 71.5% (95% confidence 
interval: 64.8-78.3) in white males (p = 0.002). Similar, prevalence differences 
were found among females age 70 years and older (p = 0.03): black females 
39.8% (95% confidence interval: 20.6-59.1) versus white females 59.0% (95% 
confidence interval: 51.3-66.8). These findings are consistent with previous 
reports within the literature regarding a decreased prevalence of age-related 
hearing loss in black individuals (Cooper, 1994; bHelzner et al., 2005; Agrawal et 
al., 2008). This is believed by some to be secondary to a hypothesized protective 
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effect of increased melanin particularly within the stria vascularis (Riley, 1997; 
Ohlemiller et al., 2009; Murillo-Cuesta et al., 2010). 
Economic status has been noted to be correlated with the presentation of 
age-related hearing loss. This may be related to the multifactorial etiology of age-
related hearing loss and the fact that undertreated otologic disease and systemic 
disease may contribute to hearing loss. Thus, individuals with higher 
socioeconomic status may have access to more preventive care and therapeutic 
treatment averting the onset or progression of hearing loss. According to the 
WHO study, individuals with an overall increased income of age 65 years and 
greater were correlated with a decreased prevalence of age-related hearing loss 
(WHO, 2012). Similar findings were reported by Lin et al. in a review of 
presbycusis prevalence in the US (bLin et al., 2011). 
 Gender has been found to impact the presentation of presbycusis. The 
male population appears to be more affected by age-related hearing loss as 
compared to their female counterparts. This has been identified in a number 
studies based both on self-reported subjective measures and objective 
audiometric data (Garstecki & Erler, 1999; Uchida et al., 2003; Gordon-Salant, 
2005; Stevens et al., 2011). In a data analysis of the National Health and 
Nutritional Examination Survey 2005-2006 cycle, hearing assessments among 
717 adults age 70 and older were reviewed. A statistically significant difference in 
the rate of presbycusis (defined as speech frequency pure tone average of 
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greater than 25 dB in the better hearing ear) was noted in males as compared to 
females, 69.8% and 58.2%, respectively (bLin et al., 2011). 
 Various epidemiological factors have been associated with the 
presentation of age-related hearing loss. As described above, international 
regional association may play a role in the rates of presentation. Socioeconomic 
status has been correlated with rates of age-related hearing loss likely secondary 
to healthcare disparities. Additionally, race and gender have been found to have 
a strong correlation with the presentation of presbycusis. 
 
Etiology 
 As presbycusis represents the sum of life influences that precipitation the 
presentation of hearing loss with aging, there are a number of factors that have 
been linked to the development of presbycusis. Gates poignantly describes 
presbycusis as “a mixture of acquired auditory stresses, trauma, and otologic 
diseases superimposed upon an intrinsic, genetically controlled, aging process” 
(Gates, 2005). The etiology of presbycusis is influenced by genetics (up to 50% 
have significant family history), cardiovascular health (in turn influenced by 
smoking and diabetes), history of noise exposure as well as, ototoxic exposure 
and otologic disorders (Parham et al, 2013). 
Aging and oxidative injury.  In a landmark article by Denham Harman in 
1956, the free-radical theory of aging was introduced (Harman, 1956). Since that 
time, free radical damage has been implicated as an etiologic factor in various 
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organ systems including the ophthalmologic, integumentary, and hepatic systems 
(Beatty et al., 2000; Justilien et al., 2007; Lu et al., 1999; Sanz et al. 1997). 
Similarly, oxidative stress has been hypothesized to be an integrally involved 
etiological factor in the development of presbycusis via free radical associated 
mitochondrial dysfunction presenting in the form of reactive oxygen species and 
reactive nitrogen species (Kidd & Bao, 2012). Various findings have been 
identified in animal studies to support this theory. Markers of oxidative stress 
have been noted to be increased in the cochlea of aged CBA/J mice (Jiang et al., 
2007). Mice missing the gene encoding copper/zinc superoxide dismutase 
(Cu/Zn superoxide dismutase), a critical enzyme in the reduction of reactive 
oxygen species and maintenance of oxidative balance, show premature 
presbycusis (McFadden et al., 1999; Keithley et al., 2005). Similarly, 
overexpression of mitochondria-localized catalase which eliminates reactive 
oxygen species has been demonstrated to be protective against age-related 
threshold shift (Someya et al., 2009). It is postulated that with the accumulation 
of mitochondrial DNA mutation, oxidative phosphorylation is impaired and 
expression of antioxidant enzymes is altered leading to further increase in 
reactive oxygen species in the cochlea (Wang et al., 2013). 
Human temporal bone studies support these findings. Various deletions 
within the mitochondrial genome have been noted in human temporal bone 
tissue (Bai et al. 1997; Fischel-Ghadsian et al., 1997; Maykaryan et al. 2008; 
Maykaryan et al. 2009; Maykaryan et al. 2010). A correlation has been identified 
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between the extent of age-related threshold shifts and mitochondrial DNA 
deletions (Bai et al. 1997; Maykaryan et al. 2009). The role of oxidative injury in 
the pathophysiology of age-related hearing loss will be further reviewed in 
Chapter 3. 
Noise.  Noise exposure is a well-established risk factor for hearing loss 
(Agrawal et al. 2008). Noise exposure contributes to oxidative stress and the 
production of reactive oxygen species which mediates short-term injury, but also 
may contribute to long-term damage. Hearing loss from noise exposure, also 
known as noise induced hearing loss, may take the form of transient threshold 
shifts or long-term acoustic changes. Everyday noise exposure can cause 
hearing loss and may accelerate the process which leading to presbycusis. Table 
2 presents the current National Institute for Occupational Safety and Health 
(NIOSH) and Occupational Safety and Health Administration (OSHA) guidelines 
for noise exposure. To put these noise exposure levels into perspective, Table 3 
provides a list of commonly and less commonly encountered noises with 
associated noise levels.  It is interesting to note that listening to high power 
headphones on a near maximum level for a period of one hour in the gym or on a 
long commute, attending a concert, or using the snow blower for over 30 minutes 
may exceed the current NIOSH recommendations for noise exposure. It is easy 
to see how simple life experiences may contribute to noise damage over time. 
Remarkably, recent studies have demonstrated that the effect of noise 
induced hearing loss may extends long after the exposure has ceased (Gates et 
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al. 2000). Noise damage occurs even with only temporary hearing loss or even 
with no immediate hearing changes noted, but this damage is believed to 
contribute to accelerated presbycusis. This is supported by findings in animal 
models of hearing loss demonstrating permanent neuronal losses in the spiral 
ganglion which has been correlated with accelerated age-related hearing loss 
(Kujawa & Liberman, 2006; Kujawa & Liberman, 2009; cLin et al., 2011) and loss 
of synaptic terminal between inner hair cells and spiral ganglion neurons (Kujawa 
& Liberman, 2009; Bao & Ohlemiller, 2010). In clinical studies, presbycusis has 
been found to be more severe in individuals thought to have suffered cochlear 
damage in their youth from noise exposure (Gates et al., 2000). 
It is important to note that presbycusis can develop in patients without a 
history of excessive noise exposure. Additionally, the shape and progression of 
hearing loss may differ in individuals with significant noise exposure. Gates et al. 
(2000) found that in subjects with noise induced threshold shifts, there is a 
reduced progression of hearing loss at 3, 4, and 6 kHz and accelerated hearing 
loss at the surrounding frequencies, particularly 2 kHz, with age which is the 
reverse of that seen in individuals without previous significant noise exposure. 
Not only does noise exposure contribute to the development of presbycusis, it 
also may impacts the character of threshold shifts associated with presbycusis. 
Hereditary Factors.  Heredity is an important factor in age-related hearing 
loss. A strong familial association has been implicated in presbycusis. This 
familial association suggests a potential genetic susceptibility to age-related 
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hearing loss (Christensen et al., 2001; McMahon et al., 2008). Approximately, 30 
to 50% of variance in presbycusis is attributed to the effects of genes (McMahon 
et al. 2008; Gates et al. 1999). Various candidate genes have been proposed; 
however, there currently is no widely accepted genetic etiology that has been 
identified. The multifactorial nature of the etiology of presbycusis poses a 
challenge in the identification of the genetic contribution to this disease process 
in clinical studies. 
Additional Etiological Factors.  As presbycusis represents the progression 
of hearing loss with aging, various additional factors have been identified that 
affect the development and progression of presbycusis. Table  4 describes 
additional etiological factors that have been proposed to contribute to the 
development of age-related hearing loss (Fowler & Jones, 1999; Hultcrantz et al., 
2006; Bao & Ohlemiller 2010; Uchida et al. 2010; Cruickshank et al. 2010; 
Kujawa & Liberman, 2006; Kujawa & Liberman, 2009; cLin et al., 2011; 
Poortinga, 2007; Seidman, 2000; Torre et al., 2004; Iwai et al., 2003; Danielidis 
et al., 2007; aHelzner et al., 2005; Picciotti et al., 2004; Torres et al., 2005; 
bFrisina et al., 2006; Antonelli et al., 1990; Johnson & Nylen, 1995; Fuente & 
McPherson, 2006; Fuente et al., 2006; Morata et al., 2002; Brant et al., 1996; 
Itoh et al., 2001; Stypulkowski, 1990; Mills et al., 1999; Chen et al., 2007; Lee et 
al., 1998; Rybak et al., 2007; Selimoglu, 2007). One major contributing factor is 
otologic disease. In theory, any otologic condition that precipitates hearing loss 
throughout life will contribute to the progression of age-related hearing loss. 
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Studies in the literature have highlighted the etiologic contribution of otosclerosis, 
chronic otitis, Meniere’s and temporal bone trauma (head trauma) to the 
presentation of age-related hearing loss (Howarth & Shone, 2006; Danielidis et 
al., 2007; Rosenhall et al., 2011).  In addition to otologic disease, ototoxins have 
been described as a contributing factor in the etiology of age-related hearing 
loss, namely aminoglycosides (e.g. gentamicin and streptomycin), platinum-
based chemotherapeutic agents (e.g. cisplatin and carboplatin), high dose loop 
diuretics (e.g. ethacrynic acid and furosemide), and salicylate and 
phosphodiesterase type 5 inhibitors (e.g. sildenafil, vardenafil, and tadalafil) 
(Stypulkowski, 1990; Mills et al., 1999; Chen et al., 2007; Lee et al., 1998; Rybak 
et al., 2007; Selimoglu, 2007; Snodgrass et al., 2010; Barreto & Bahmad, 2013). 
Toxic exposures such as heavy metals (e.g. lead and mercury) and solvents 
(e.g.toluene, styrene and xylene) also have been implicated (Johnson & Nylen, 
1995; Morata et al., 2002; Fuente & McPherson, 2006; Fuente et al., 2006). 
Tobacco and alcohol abuse have been proposed as etiologic factors in 
presbycusis; however there are conflicting reports within the literature with this 
regard (Brant et al., 1996; Itoh et al., 2001). In multiple studies, cardiovascular 
disease and diabetes have been associated with the progression of presbycusis 
(Picciotti et al., 2004; Torre et al., 2005; Fowler & Jones, 1999; bFrisina et al., 
2006; Diniz & Guida, 2009; Ren et al., 2009; Uchida et al. 2010;). Additionally 
renal failure and impaired immune function may play a contributing role (Anotelli 
et al., 1990; Iwai et al., 2003). 
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A number of factors have been found to be protective against the 
progression of age-related threshold shift. Hormonal function including 
aldosterone and estrogen have been found to be protective against age-related 
changes in hearing (Tadros et al., 2005; Hultcrantz et al., 2006). Higher levels of 
bone mineral density have been correlated with decreased rate of change in 
hearing with age (aHelzner et al., 2005). Additionally, caloric restriction may play 
a preventative role (Seidman, 2000; Torre et al., 2004). Further study is required 
to fully elucidate these effects. 
 
 
Impact of Presbycusis  
 The impact of age-related hearing loss is not limited to merely the ability of 
an individual to hearing and comprehend speech. The impact of presbycusis is 
far reaching. It not only impacts the individual from a psychosocial perspective 
and potentially increases the progression of dementia, but it also has a significant 
public health impact internationally. 
Psychosocial Impact.  The psychosocial impact of presbycusis has been 
well established. With progression, presbycusis typically precipitated difficulty 
with speech discrimination and word understanding particularly in ambient 
situations. This translates to difficulty participating in conversation at a busy 
restaurant or understanding the punch line of a joke at a family gathering. 
Although this may seem minor, for many individual this can produce significant 
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embarrassment and frustration. Social isolation and anxiety in social situation 
have been described in association (Cacciatore et al., 1999; Bernabei et al., 
2011). In countless patients, this progresses to decreased autonomy and 
depression significantly impacting their activity level and social interconnectivity 
(Uhlmann et al., 1989; Kalayam et al. 1995; Heine & Browning, 2002; Dalton et 
al., 2003; Kramer et al. 2008; Mohlman, 2009; Bernabei et al., 2011). This has 
been associated with a significant decline in overall quality of life reported by 
individuals affected with presbycusis (Li-Korotky, 2012; Ciobra et al., 2012). 
Association with dementia.  The association between dementia and age-
related hearing loss has been described for decades within the literature. 
However, our understanding of the impact that presbycusis plays on the 
progression of dementia has evolved significantly. Within the mid-1980s, various 
publications were produces revealing the significant correlation between hearing 
impairment in the elderly and the progression of dementia (Uhlmann et al., 1989; 
Uhlmann et al., 1986; Weinstein & Amsel, 1986). Global functional decline also 
has been noted in association with age-related hearing loss shy of the clinical 
diagnosis of dementia within this population (Herbst & Humprey, 1980; LaForge 
et al., 1992; Cacciatore et al., 1999). A direct positive correlation between degree 
of hearing loss and cognitive decline has been noted on both verbal and non-
verbal cognitive testing within numerous reports in the literature (Ohta et al., 
1981; Peters et al., 1988; Uhlmann et al. 1989; Lindenberger & Baltes, 1994; 
Gussekloo et al., 2005; Tay et al., 2006; Valentijn et al., 2005). More recently, 
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this association has been further quantified. Among individuals free of dementia 
or mild cognitive impairment, the impact of the degree of hearing loss was 
quantitatively associated with decline in cognitive function. It was noted that a 25 
dB hearing loss produces a decline equivalent to an age difference of 6.8 years 
on test of executive function (Lin, 2011; aLin et al., 2011). Additional study is 
require to further investigate this potential causative relationship. 
Public Health Impact.  Presbycusis poses a significant public health 
concern internationally. The percentage of the population over the age of 65 is 
projected to grow internationally over the ensuing decades (Kinsella & Wan, 
2008). As such, the prevalence of age relating hearing loss will increase 
precipitously. According to the World Health Organization (WHO) hearing loss is 
one of the six leading contributors to the burden of disease in industrialized 
countries (Mathers et al., 2000). Based upon the WHO 2012 Hearing Loss 
Estimate, adults make up 91% of individuals internationally with disabling hearing 
loss, when defined as greater than or equal to 40 dB of hearing loss, accounting 
for 328 million of 360 million total individuals internationally affected (WHO, 
2012). Adults over the age of 64 years make up more than half of all adults with 
hearing loss (Schiller et al., 2012).  It is projected by 2025 that there will be 1.2 
billion people over 60 years of age worldwide, with more than 500 million 
individuals who will suffer significant hearing impairment from presbycusis 
(Sprinzl & Riechelmann, 2010). Additionally, presbycusis may contribute to early 
 
19 
 
undesired retirement and decreased workforce participation creating a significant 
economic impact.  
 
Schuknecht Classification 
Pathophysiological changes have been noted in various components of 
the auditory system in association with age-related hearing loss. Traditionally, 
presbycusis was believed to be a disorder of the peripheral auditory system, 
namely the cochlea. Schuknecht developed a classification system which 
highlights the cochlear changes that have been noted in association with age-
related hearing loss (Schuknecht, 1964; Ramadan & Schuknecht, 1989). Figures 
3 to 6 depicts audiograms that would accompany four of the classic 
classifications of presbycusis proposed by Schuknect. Sensory presbycusis is 
characterized by slowly progressive, bilateral steep down-sloping high frequency 
hearing loss associated with loss of cochlear hair cells particularly at the basal 
turn of the cochlea (Figure 3). Neural presbycusis is characterized by a decline in 
speech discrimination associated with spiral ganglion cell loss (Figure 4). 
Metabolic presbycusis is characterized by flat hearing loss attributed to atrophy 
within the stria vascularis (Figure 5). Mechanical presbycusis is associated with a 
gradual descending pattern of hearing loss presumed to occur as a function of 
stiffening of the basilar membrane (Figure 6). The most common form 
encountered is mixed presbycusis which encompasses flat, sloping or high 
frequency hearing loss and is associated with a combination of hair cell, spiral 
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ganglion, and strial losses (Schuknecht & Gacek, 1993). In addition to the 
histopathologic changes described within the Schuknecht classification system, 
various cochlear changes have been described in association with aging 
including loss of outer hair cells and support cells, changes in hair cell stereocilia, 
vascular changes in the stria vascularis, decreased synapses particularly at the 
basal turn, and loss of nerve fibers and ganglion cells (Nadol, 1979; Suga & 
Lindsay, 1976; Felder & Schrott-Fischer, 1995; Scholtz et al., 2001; Nelson & 
Hinojosa, 2003; Nelson & Hinojosa, 2006).  The histopathology and molecular 
pathophysiology of the peripheral pathway in presbycusis will be further reviewed 
in Section 2.2.  
 
 
Clinical Evaluation 
The clinical evaluation of patients present with age-related hearing loss 
often begins with the primary care provider. Primary care providers including 
gerontologists are typically charged with the responsibility of coordinating the 
care of elderly patients. Referral for audiometric evaluation should be including in 
the routine evaluation of the geriatric patients. This appears as one of the goals 
of United States National Institutes of Health (NIH) Healthy People 2020 (ENT-
VSL-5: increase the number of persons who are referred by their primary care 
physician or other health care provider for hearing evaluation and treatment) 
(NIH 2014). It is essential to realize that individuals with early presbycusis may 
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minimize their symptoms. Patients with presbycusis may initially be reluctant to 
admit that they are experiencing hearing loss. Alternatively, some individuals 
view hearing loss as a normal process of aging “like wrinkles” or perceive it as 
something that they must suffer through. Therefore, regardless of the patient 
report among the geriatric population, referral for audiometric evaluation should 
be made at least every 5 years. This is in accordance with the NIH Healthy 
People 2020 objective ENT-VSL-4 which aspires to increase the proportion of 
persons who have had hearing examination on schedule which is suggested as 
within a 5 year period (NIH 2014). 
 On clinical presentation, patients typically present with high frequency 
sensorineural hearing loss accompanied by decline in speech discrimination and 
speech understanding. Patients may report particular difficulty understanding 
conversation in ambient conditions. They may report complaints or their family 
may report that they complain that others tend to mumble or slur their words. 
Individuals with presbycusis often report that men’s voices are easier to hear and 
understand than women’s and children’s voices.  
A major related complaint of patients with presbycusis is its associated 
tinnitus. As the hearing loss progresses, tinnitus tends to progress as well. The 
tinnitus may present as intermittent, but typically becomes constant with 
progression of hearing loss. 
 The clinical evaluation of patient should include a complete head and neck 
examination with cranial nerve evaluation and otologic evaluation. Audiometric 
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evaluation should be performed including pure tone audiometry, speech 
discrimination, tympanometry and acoustic reflexes. Typical findings are of 
symmetric high frequency sensorineural hearing loss.  Imaging of the temporal 
bone or skull base is typically not indicated with normal otologic examination and 
characteristic audiometric findings. If asymmetric hearing loss or otologic 
abnormalities are noted, clinical discretion should direct imaging. 
 
 
Prevention 
The key to prevention of age-related hearing loss is avoidance of factors 
that can promote or accelerate its progression. Adequate treatment of potentially 
contributing otologic disease should be employed. Ototoxins should be avoided 
when possible. Potential contributing comorbidities should actively and 
aggressively be managed to prevent associated threshold shifts. 
Prevention of noise trauma is a major component of prevention of age-
related hearing loss.  Patient should avoid excessive noise exposure. When 
noise exposure is unavoidable (e.g. occupational requirements or recreation), 
adequate noise protective equipment should be utilized to dampen noise 
exposures. Insert ear plugs provide approximately 15 to 25 dB of sound 
attenuation. Alternatively, noise protection ear muffs provide approximately 20 to 
30 dB of sound attenuation. For individuals with high acoustic professional 
demand with significant noise exposure (i.e. musicians, music teachers, 
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recording engineers or sound crew members), high fidelity hearing protection or 
musicians ear plugs are recommended. These customized ear plugs reduce 
sound level presented to the ear while maintaining clear and nature sound 
without muffled character as experienced with traditional ear plugs. The level of 
attenuation too is customizable.  
 
 
Management 
 The mainstay of management of age-related hearing loss is environmental 
optimization and auditory rehabilitation. Auditory rehabilitation takes many forms 
ranging from simple assistive devices to cochlear implantation. There currently 
are no medical therapies available for the treatment or prevention of age-related 
hearing loss. This presents a significant opportunity for future research and 
development. 
Environmental Optimization. Patient with presbycusis, whenever possible, 
should make modifications to their environment to optimize their auditory milieu. 
This may take the form of turning off televisions or decreasing the volume of 
background music during dinner conversations or sitting in a favorable location to 
facilitate face to face conversation to not only allow for lip reading, but also use of 
nonverbal cues (i.e. facial expression and gestures) to augment speech 
understanding. If comfortable, individuals may request speakers to speak more 
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slowly as comprehension of rapid speakers is commonly impaired in individuals 
with presbycusis. 
Auditory Assistive Devices.  Hearing assistive devices are non-
prescription, non-personalized aids that augment environmental sounds or 
provide alternatives to challenging acoustic situation. These devices include such 
devices as telephone amplifiers, television amplifiers, alarm clocks with vibrators, 
frequency-modulation transmitters, doorbell signalers, and modified smoke 
detectors. These devices are of great benefit to patient with age-related hearing 
loss, but are limited in their ability to assist in the most challenging of 
communication situations. 
Hearing Aids.  Hearing aids represent the mainstay of treatment for age-
related hearing loss. Hearing aids are typically recommended for sound 
amplification in individuals with hearing thresholds within the speech frequencies 
of 40 dB or greater. In selective cases where employment or educational 
demands are unusually demanding, individuals with losses of less than 40 dB 
may derive benefit from amplification.  
 Currently available hearing aids are mainly digital, although analogue 
devices remain on the market. Recent advances in hearing aid technology have 
leant to the development of enhanced features to improve sound appreciation 
and functionality including noise suppression technology, telephone coils, and 
multiple programming modes optimized for quiet, noise, or music appreciation. 
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These features are accessible manually or in some cases with automatic smart 
technologies.  
Unfortunately, hearing aids are not covered by many healthcare plans and 
for countless patients the cost of the devices is prohibitive. Within the United 
States, fewer than 25% of patients affected by presbycusis who would benefit 
from hearing aids use them (Kochkin & MarkeTrak, 2009; Popelka et al., 1998).  
Amongst individuals with presbycusis who do not use hearing aids, 76% indicate 
that the cost is a significant reason for not using hearing aids and 64% simply 
state that they cannot afford hearing aids (Henkel, 2009). Conversely, in health 
systems where hearing aids are a covered benefit, elder hearing-impaired 
hearing aid use is greater than 60% (Corna et al., 2009). As hearing aid use has 
been reported to improve quality of life (Tsakiropoulou et al, 2007), increasing 
hearing aid availability provides a significant opportunity to improve public health 
internationally. 
Hearing aid use does require a period of cognitive adaptation. 
Unfortunately, for some patients intermittent use precipitates dissatisfaction 
secondary to lack of complete adaptation to the hearing aid device. In a study of 
hearing aid use amongst individuals 70 years and older, use of 5 hours or greater 
was reported in only 19.1% of individuals (bLin et al. 2011). The rate of use was 
noted to be dependent upon the degree of hearing loss with reported use rates of 
3.4% for individuals with mild hearing loss, 40% for individuals with moderate 
hearing loss, and 76% for individuals with severe hearing loss (bLin et al. 2011). 
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This data is similar to previous reports within the literature of underuse or 
abandonment of hearing aids of 25% and 40% underuse or abandon (Gates et 
al., 1990; Hanratty & Lawlor, 2000). The most commonly reported reasons for 
abandoning hearing aid use or underusing the technology are problems with fit or 
understanding the operation of the device as well as unmet expectation (Gates et 
al. 1990; Kochkin & Marke Trak, 2000; Ovegard & Ramstrom, 1994; Popelka et 
al., 1998; Smeeth et al., 2002; McCormack & Fornum, 2013). Thus, adequate 
education and establishment of realistic expectations are critical to hearing aid 
acceptance, adaptation and use.  
Cochlear Implants.  For patients with severe to profound bilateral 
sensorineural hearing loss, cochlear implantation may be an option. Cochlear 
implantation is recommended for patients who do not derive benefit from hearing 
aid use and meet certain criteria for speech discrimination testing (i.e. score 50% 
or less on sentence recognition testing in their worse hearing ear and 60% or 
less in the bilateral best aided conditions). However, criteria for cochlear 
implantation is continually evolving and broadening to encompass individuals 
with a greater degree of residual hearing. Within the geriatric population, the 
procedure is typically performed in the outpatient setting unless precluded by 
medical comorbidities. It is well tolerated with low surgical morbidity and high 
rates of success with significant improvement in quality of life (Poissant et al., 
2008; Coelho et al., 2009; Budenz et al., 2011; Sanchez-Cuadro et al., 2013; 
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Lenarz et al., 2012; Lin et al., 2012).  Interestingly, unlike hearing aids, cochlear 
implantation is covered by most healthcare plans. 
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Section 2.2: Histopathology and Pathophysiology of ARHL 
Various histopathologic finding have been associated with age-related 
hearing loss. These changes have been noted throughout the cochlea with some 
central changes reported within the recent literature. The cellular losses and 
histopathologic changes are believed to be instrumental in the clinical 
presentation of presbycusis. 
 With regard to cellular changes, loss of sensory hair cells and spiral 
ganglion cells have been reported; additionally, accumulation of lipofuscin, 
collection of lysosomal granules and absence of hair cell stereocilia have been 
associated (Nadol, 1979; Bohner et al, 1990; Schuknecht and Gacek, 1993; 
Mizuta et al, 1993; Adams et al, 1997; Ingham et al, 1999; Meyer zum 
Gottesberge et al, 2001; Scholtz et al, 2001; Juhn et al 2005). In addition to the 
age-related degeneration of the hair cells within the auditory pathway, 
degeneration of the cochlear lateral wall is considered to be another important 
mechanism of presbycusis (Ichimiya et al., 2000; Hequembourg and Lieberman, 
2001). Tang et al (2014) illustrated that the lateral wall structures are crucial in 
the maintenance of endolymphatic potassium levels, endocochlear potentials and 
ion homeostasis within the cochlea. In studies of aging animals, increased 
apoptosis and atrophy have been noted within the lateral wall (Thomopoulos et al 
1997; Suzuki et al, 2006, Juhn et al., 2005).  
Studies indicate that the cochlear lateral wall may play a larger role in the 
pathogenesis of age-related hearing loss than previously acknowledged. A 
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number of vascular changes have been noted in the cochlear lateral wall. 
Thickening of the basement membrane of capillaries in the stria vascularis has 
been observed (Thomopoulos et al 1997; Juhn et al., 2005; Suzuki et al, 2006). 
These reports in the literature have suggested that age-related changes in the 
lateral wall of the cochlea, namely, observed thickening of the basement 
membrane of capillaries in the stria vascularis, may contribute to degenerative 
changes within the strial epithelial cells (Thomopoulos et al 1997; Suzuki et al, 
2006). Additionally, thickening of the lamina densa within the stria vascularis and 
spiral ligament of aged rats when compared to young rats has been described. 
Immunohistochemical studies of the basement membrane (BM) have 
demonstrated increased deposition of laminins and immunoglobins (Sakaguchi et 
al, 1997a; Sakaguchi et al, 1997b). Immunohistochemical analysis of C57BL/6J 
mouse temporal bones demonstrated expression of vascular endothelial growth 
factor (VEGF) in the stria vascularis, spiral ligament and spiral ganglion cells of 
young mice (Picciotti et al., 2004).  However, aged mice demonstrated a 
significant decrease in immunoreactivity in all of the aforementioned areas.  
Specific cochlear VEGF receptor, Flt-1 and Flk-1, expression was also evaluated.  
The Flt-1 receptor was found to be present in the organ of Corti, stria vascularis 
and spiral ligament in young mice, while aged mice had little to no 
immunoreactivity present in the organ of Corti, with expression in the stria 
vascularis and spiral ligament virtually unchanged.  However, the Flk-1 receptor 
was present in the stria vascularis, spiral ganglion cells, modiolus, and the basilar 
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membrane and was virtually unchanged in the aged animals. Similar results were 
reported by Clinkard et al (Clinkard et al. 2013). Within the C57BL/6 mouse 
model, significant decreases in strial area, blood vessel number, luminal size, 
and luminal area were noted when comparing mice age 4 weeks to age 32-36 
weeks of age. Additionally, significant up-regulation of Flt-1 was noted in aged 
mice with no change noted in Flk-1 receptor expression.  However within Swiss 
Webster mice, these findings were not replicated (Kandasamy et al., 2012). No 
changes in VEGF, Flt-1 or Flk-1 were noted in aged Swiss Webster mice as 
compared to younger mice. None the less, this finding in the majority of reports in 
the literature implies decreased permeability, which may cause slowed diffusion 
of ions, metabolites, and oxygen through capillaries. This may ultimately result in 
disturbance of ion homeostasis. 
Changes have been observed within the fibrocytes of the lateral wall in 
association with the aging process. Fibrocytes play a critical role in potassium 
ions recycling and the maintenance of the endocochlear potential; potassium is 
transported via a network of gap junctions between the fibrocytes within the 
lateral wall to be re-released in to the endolymph. Hequembourg and Liberman 
(2001) found age-related widespread degeneration of fibrocytes in the spiral 
ligament, especially among the type IV cell class within the C57BL/6 mice. These 
changes were found to precede inner and outer hair cell loss in the organ of 
Corti.  
 
31 
 
Kusunoki et al. (2004) studied the temporal bones of individuals aged 1 
day to 86 years and identified a number of histopathologic changes with aging. In 
addition to loss of hair cells and spiral ganglion cell, they identified a statistically 
significant increase in the area of the stria vascularis in the lower basal turn of 
temporal bones of infants when compared to elderly patients. There was a 
significant correlation between advancing age and loss of fibrocytes in the spiral 
ligament. A loss of type II and IV fibrocytes was found to precede the loss of type 
I and III fibrocytes. Additionally, a greater loss was observed of type II and IV 
fibrocytes when compare to type I and III fibrocytes. Loss of fibrocytes implies 
impair potassium transport and maintenance of endocochlear potential.  
A number of additional findings on immunohistochemical analysis of aging 
animals indicate impaired potassium ion transport as a crucial factor in 
presbycusis. Decreased expression of connexins has been observed with aging 
in atrophic endothelium and brain astrocytes (Yeh et al., 2000; Cotrina et al., 
2001). Similarly, connexins, within the cochlear lateral wall, form gap junctions 
between fibrocytes allowing for the transport of potassium ion to be recycled into 
the endolymph. Ichimiya et al. (2000) observed a decrease in expression of 
connexin 26 in the cochlear lateral wall of the C57BL/6 mice as well as 
disorganization of the organ of Corti and a decrease in the number of spiral 
ganglion cells. Na+-K+-ATPase immunolabeling was also increased in the spiral 
ligament. Spicer et al. (1997) examined the temporal bones of young and aged 
gerbils and found alterations in Na+-K+-ATPase, carbonic anhydrase or creatine 
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kinase level by immunohistochemical analysis within the stria vascularis and 
spiral ligament. Age-dependent degeneration and loss of Na+-K+-ATPase in the 
stria vascularis was found to occur predominantly in the apex, lower base and 
hook of the cochlea. Na+-K+-ATPase, carbonic anhydrase and creatine kinase 
immunostaining intensity in fibrocytes changed in relation to the decline in strial 
marginal cell Na+-K+-ATPase activity, revealing up-regulation followed by down-
regulation. These finding indicate that strial changes may precede changes 
within the spiral ligament, but support the notion that ion homeostasis is crucial in 
the pathogenesis of presbycusis. Spiess et al. (2002) also observed 
vacuolization and degeneration of type II and IV fibrocytes which was found to be 
more pronounced in areas of advanced strial degeneration. They attributed this 
vacuolization and degeneration in ATPase-rich fibrocytes and the associated 
intercellular edema to a secondary responses, possibly as a result of impaired 
diffusion of potassium through downstream marginal cells. Changes in marginal 
cell morphology have also been identified with the aging process, namely 
alterations in primary and secondary processes (Spicer & Schulte, 2005).   
These findings within the lateral wall imply the possibility of decreased 
potassium recycling, impaired ion homeostasis and altered endocochlear 
potentials as a probable contributing etiology of age-related changes. In fact, 
Schmiedt (1996) reported decreased endocochlear potentials in a gerbil model in 
association with similar finding within the cochlear lateral wall. Additionally, Wu 
and Markus (2003) found reduced potassium concentrations by 30% in the basal 
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and apical turn of aged CD-1 mice, an accelerated model of hearing loss. The 
endocochlear potentials were also found to be reduced in magnitude. Severe 
loss of cells within the region of type IV fibrocytes was also observed in the basal 
and apical turns; type II fibrocytes loss was observed in the basal turn. 
Histopathologic changes in the lateral wall appear to be essential in potassium 
homeostasis derangement and alteration of endocochlear potential. 
In addition to the previously proposed peripheral histopathology related to 
age-related hearing loss, recent evidence supports a central component to age-
related hearing loss citing the fact that auditory performance in elderly individuals 
is largely impacted by decreased spiral ganglion cells, decreased central 
plasticity, central auditory processing disorder, as well as increased incidence of 
central nervous system disease and cognitive decline (Gates et al., 2010; 
Parham et al., 2013). Central presbycusis likely represents a component of the 
overall presentation of presbycusis rather than an isolated entity in and of itself 
(Humes et al. 2012). Further study is require to better characterize the central 
component of presbycusis. 
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Section 2.3: Oxidative Injury and Antioxidants in Age-Related 
Hearing Loss 
The diversity of histopathologic changes identified within the cochlea in 
association with presbycusis as well as the variability in onset and severity 
encountered clinically with presbycusis implies a multifactorial etiology.  A 
number of factors have been proposed to contribute to the presentation of 
presbycusis. These factors include oxidative stress, decreased stress defense 
mechanism, exogenous factors and genetics.  Age-related changes in the 
cochlea are proposed to be a function of both genetics and environmental 
stresses, which lead to alterations in electrolyte homeostasis and cellular 
metabolism (Petropoulou et al, 2000). These alterations may affect various 
pathways leading to loss of membrane integrity, changes in ion permeability, 
damage to cellular structures, generation of toxic oxygen species and free 
radicals, and dysfunction of intracellular transport mechanisms. 
Oxidative injury has been well classified as an etiologic factor in the process 
of aging. Oxidative injury caused by free radical damage is perhaps the most 
fundamental cause of age-related pathology in the biological aging of cells and 
may be an important intrinsic factor in presbycusis. Increased concentrations of 
free radicals such as reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) are implicated as a mediator of oxidative stress, inflammatory and 
infection-related damage in the central nervous system (CNS) and other tissues.  
ROS comprise superoxide free-radicals, hydrogen peroxides and hydroxyl 
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radicals.  Concurrent with the increase in ROS is a decreased production of 
function of the endogenous enzymes that protect the cell against ROS damage 
including superoxide dismutase (SOD), catalase and glutathione peroxidase.  
These ROS have been shown to contribute in part to producing mitochondrial 
DNA (mtDNA) damage by causing deletions in the mitochondrial genome 
(Seidman et al., 2004).  The main contributor to RNS is the gaseous transmitter, 
nitric oxide (NO).  NO and its oxidation products, such as peroxynitrite, have 
been shown to be potent cellular mutagens and cytotoxic agents which may 
inflict accumulating damage to normal cells (Cooney and Mordan, 1995).  The 
increased release of NO may cause pathological conditions of the stria 
vascularis.  ROS may contribute to presbycusis by damaging metabolically active 
tissues of the inner ear structure (e.g. stria vascularis).   
Nitric oxide may play a critical role in the progression of disease in 
presbycusis. Nitric oxide is a highly diffusible cellular mediator with potent 
mutagenic and cytotoxic potential, which is capable of causing accumulated 
damage in normal cells (Cooney and Mordan, 1995). Additionally, nitric oxide, 
when overproduced, is a pro-apoptotic modulator that functions by activating the 
caspase family of proteases within the cochlea (Chung et al, 2001). For these 
reasons, nitric oxide may be a critical component of cochlear damage in age-
related hearing loss.  
Within the cochlear, nitric oxide is produce by i-nitric oxide synthase (iNOS). 
Preliminary data revealed elevation in the expression of iNOS in the lateral wall 
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of aged animal when compared to young animals. NOS inhibitors, such as NW-
nitro-L-arginine-methyl ester (L-NAME), may slow or prevent the production of 
nitric oxide within the cochlea and its subsequent injury. L-NAME has been 
reported to block vestibular hair cell degeneration (Takumida and Anniko, 2000). 
Thus, iNOS inhibitor, like L-NAME, could potentially prevent the oxidative 
damage created by the presence of nitric oxide in the cochlea in ARHL. 
Glutathione is an important ubiquitous antioxidant found in the inner ear. 
Lautermann et al. (1997) found reduced levels of glutathione in the inner ear of 
aged Fisher 344 rats when compared to young rats. We have observed inducible 
nitric oxide synthase (iNOS) immunoreactivity in the stria vascularis of aged 
animals while no iNOS expression was detected in that of young rats.  Moreover, 
cultured marginal cells of the stria vascularis exposed to NO with sodium 
nitroprusside (SNP) as an NO donor exhibited elevation of intracellular calcium.  
This may be related to the NO-induced cellular apoptosis identified in the aging 
lateral wall (Juhn et al., 2006).   
Deletions in the mitochondrial genome have been reported in association with 
presbycusis. The high incidence of mitochondrial (mt)DNA4977 deletion in the 
temporal bones of presbycusis patients suggests a correlation between the 
mtDNA4977 deletion and presbycusis (Bai et al., 1997).  Dai et al. (2004) reported 
that the mtDNA4977 deletion was accompanied by a narrowing of the inner ear 
blood vessels.  They speculated that the narrowing of those vessels would cause 
hypoxia of the inner ear and initiate a chain of episodes including ischemia in the 
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inner ear, malfunction of oxygen metabolism, reduction in the level of oxidative 
phosphorylation, elevation of free radicals, damage of mtDNA, and accumulation 
of mtDNA4977 deletion and other mtDNA mutants.  Resultant malfunction of the 
mitochondria and impaired oxidative phosphorylation ultimately accelerates the 
degeneration and death of cells in the organ of Corti and the nerve fibers of the 
inner ear (Dai et al., 2004; Seidman et al., 2004; Fischel-Ghodsian et al., 2004). 
Another aspect of the aging process can be represented by decreased ability 
of the body to defend itself against environmental insults.  The inner ear and its 
associated structures sustain damage throughout life. Heat shock proteins 
(HSPs) are involved in major defense mechanisms within the inner ear.  HSPs 
are proteins that are involved in protecting cells from a variety of stress by 
binding to denatured proteins and assisting in proper refolding.  It has been 
reported that oxidative stress can induce the expression of HSPs, and pre-
treatment increases the protection of cells for subsequent oxidative stress (Luna 
et al., 2000; Grosslau and Rensing, 2000; Smolka et al., 2000).  Therefore, if the 
level of HSPs decreases with aging, it will indirectly accelerate age-related 
changes by not protecting cells effectively against various cellular stresses 
including oxidative stress.  It has been reported that HSP70 mRNA level 
decreased with aging (Bernstein et al., 2000; Fargnoli et al., 1990). Investigation 
of HSP70 immunoreactivity in the stria vascularis of young and old rats has been 
reported to reveal reduced expression of HSP70 in old rats as compared to 
young rats (Juhn et al., 2002).  This finding was found to correlate with elevations 
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in ABR thresholds at all frequencies in old rats as compared to young rats (Juhn 
et al., 2002).    
Additionally, antioxidants also may prevent or retard oxidative damage that 
occurs in the cochlear lateral wall in association with age-related hearing loss. 
Antioxidants have been demonstrated to improve high frequency auditory 
sensitivities with human and animal models (Seidman, 2000; Takumida and 
Anniko, 2005). Reactive oxygen species (ROS) is considered to be involved in 
the mechanism of hearing loss.  Many intrinsic enzymes, such as superoxide 
dismutase (Fridovich, 1981), catalase (Warholm et al., 1981) and glutathione 
transferase (Flohe, 1985) have been reported to protect cells from oxidative 
damage.  It has been reported that antioxidant mechanisms require the action of 
a variety of small molecules in the diet, such as vitamin E (tocopherol) and 
vitamin C, which trap radicals in lipid and water-soluble membranes and reduce 
oxidative stress (Bieri et al., 1983).  Seidman (2000) demonstrated that 
intervention designed to reduce reactive oxygen metabolites damage using 
antioxidants, such as vitamin E, vitamin C, and melatonin, can protect against 
age-related hearing loss.  Takumida and Anniko (2005) also demonstrated that 
daily oral treatment with rebamipide and vitamin C in patients with age-
associated hearing loss significantly improved pure tone hearing level thresholds 
at 125, 250, 500 and 8,000 Hz, but with no significant changes at 1, 2 and 4 kHz.  
Recently, a new prodrug, L-CySSG, was shown to abrogate hepatotoxicity 
induced by the ROS (Berkeley et al., 2003). Durga et al. (2007) reported slowing 
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of hearing decline in elderly patients following a 3-year dietary supplementation 
of folic acid. Derin et al. (2004) found improvement of age-related hearing 
deterioration in Wistar rats with administration of L-carnitine. Le et al. (2007) 
reported decreased cochlear degeneration in a group of mice treated with a 
combination lipoic acid and l-carnitine diet. Most recently, Seidman and 
colleagues (2008) a reduction in progression of ARHL and decreased expression 
of cycloxygenase-2 and 5-lipoxygenase in Fisher 344 rats with the administration 
of resveratrol, an antioxidant derived from the extract of grapes and red wine. 
Mikuriya et al (2008) reported that the administration of geranylgeranylacetone 
(GGA), which is a heat shock protein inducer, suppresses age-related hearing 
loss in DBA/2J mice.  
 In addition to nitric oxide related damage, hydrogen peroxide and reactive 
oxygen species have been known to produce toxicity in the cochlea. Superoxide 
dismutase, catalase and glutathione normally detoxify these free-radicals within 
the cochlea (Staecker et al 2001). Glutathione (GSH), an endogenous cellular 
antioxidant present in the cochlea, is a tripeptide consisting of L-cysteine (Cys), 
L-glutamic acid (Glu), and glycine (Gly). It is biosynthesized in a two-step, 
catalyzed by the enzymes gamma-glutamylcysteine synthetase and glutathione 
synthetase. Herbert T. Nagasawa, Professor of Medicinal Chemistry and 
Toxicology at the University of Minnesota, has developed a diverse series of L-
Cys and GSH prodrug antioxidants for the treatment of drug-induced 
hepatotoxicity which is mediated by oxidative damage. Recently, he has 
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identified L-cysteine-glutathione mixed disulfide (L-CySSG), a mixed disulfide of 
Cys and GSH, and he has shown that this sufhydryl-modified GSH prodrug is 
highly effective in protecting the liver from hepatotoxicity in a mouse model of 
oxidative stress induced by acetaminophen (Berkely et al, 2003). The 
consequence of cumulative oxidative stress is depletion of the cellular antioxidant 
GSH in cochlear cells, resulting in lack of protection from oxidants, loss of 
cochlear outer hair cells and diminution in high frequency hearing acuity. Thus, L-
CySSG may be a potential protector against oxidative stress in the cochlea as it 
has been described to be in the liver. 
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Section 2.4: C57BL/6 Mice as an Animal Model of ARHL 
The clinical study of ARHL is limited by the capability to perform 
longitudinal study given the protracted time course of onset and progression of 
age-related hearing loss in the patient population. For this reason, animal models 
have commonly been utilized for the study of the histopathology, pathophysiology 
and potential treatment of ARHL. One of the most common animal models used 
for the study of presbycusis is the C57BL/6 mouse model.  
The C57BL/6 mouse model is an accepted model of ARHL which has 
extensively been studied for decades (Mikaelian, 1979; Henry & Chole, 1980;  
Shone et el., 1991; Willott, 1991; Kazee et al., 1995; Spongr et al., 1997; 
Hequembourg & Liberman, 2001). The hearing loss described in this strain of 
mice has been well characterized and documented within the literature. As in 
presbycusis, age-related threshold shifts in C57BL/6 mice begin at the high 
frequencies. Also similarly, hearing loss begins well after the mice have reached 
sexual maturity (sexual maturity between 6 to 8 weeks of age; the onset of 
hearing loss approximately 5 to 6 months of age). These mice experience 
progressive high frequency sensorineural hearing loss as in the human 
population thereafter in addition to later onset low frequency sensorineural 
hearing loss. Complete deafness typically occurs by 18 months of age. In 
addition to changes in auditory physiology which mirror that of clinical 
presbycusis, histopathological changes have been documented within the 
C57BL/6 mice to mirror those noted in human temporal bone studies with aging.   
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Chapter 2.5: Rodent Anesthesia for Auditory Brainstem 
Response Testing 
Ketamine and Xylazine  
Ketamine is a controlled substance which is classified as a dissociative 
agent. Ketamine alone is known to provide analgesia, but lacks the ability to 
provide relaxation (Smith, 1993; Erhardt et al., 1984; Arras et al. 2001). A major 
adverse response to ketamine in the rodent population is life-threatening tremor 
and tonic-clonic convulsions (Green et al., 1981). 
Xylazine is an 2-agonist commonly used in veterinary and research 
anesthesia. Unlike ketamine, xylazine provides both analgesia and sedation. 
Xylazine is known to be a potent hypnotic with powerful central muscular relaxant 
properties (Green et al., 1981). Xylazine is has been documented to precipitate 
cardiac arrhythmia (Green et al. 1981). 
Together, ketamine and xylazine are one of the mostly utilized 
combination anesthetics utilized for rodent anesthesia (Buitrago et al., 2008; 
Arras et al., 2001; Chaves et al., 2003; Deschepper et al., 2004; Flecknell, 1996; 
Furukawa et al., 1998; Hart et al., 2001; Janssen et al., 2004; Kawahara et al. 
2005; Lorenz, 2002; Roth et al., 2002; Yang et al., 1999; Zuurbier et al., 2002). 
The recommended injectable dose of anesthetic for mice varies substantially in 
the literature secondary to differences in operators, mouse strains and a 
combined effect (Buitrago et al., 2008; Arras et al., 2001). The published dosage 
ranges from 80 to 200 mg/kg for ketamine and 0.5 to 10 mg/kg for xylazine 
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(Buitrago et al., 2008; Arras et al., 2001; Chaves et al., 2003; Deschepper et al., 
2004; Flecknell, 1996; Furukawa et al., 1998; Hart et al., 2001; Janssen et al., 
2004; Kawahara et al. 2005; Lorenz, 2002; Roth et al., 2002; Yang et al., 1999; 
Zuurbier et al., 2002). Potential adverse effects that have been reported in the 
literature with ketamine and xylazine administration in mice include profound 
bradycardia (Chaves et al., 2001; Fuentes et al., 2006; Hoit et al., 1997; Ishizaka 
et al., 2004; Roth et al., 2002; Hart et al., 2001), cardiac depression (Hoit et al., 
1997; Kawahara et al., 2005; Roth et al., 2002), hypotension (Fuentes et al., 
2006; Hoit et al., 1997; Ishizaka et al., 2004; Kawahara et al., 2005; Roth et al., 
2002), and death (Arras et al., 2001). Of importance for longitudinal studies in 
which mice will be administered multiple dosages of anesthesia, a death rate as 
high as 40% has been reported in association with ketamine and xylazine 
administration within the literature (Arras et al., 2001).  
 Ketamine and xylazine has become the gold standard for mouse 
anesthesia in auditory brainstem response testing (van Looij et al., 2004; Henry 
2002; Huang et al., 1995; Jero et al., 2001; Miller et al., 1998; Ou et al., 2000). 
Interestingly, ketamine and xylazine has been documented to alter waveform 
structure in auditory brainstem response testing, increase wave latencies by as 
much as 1ms and decrease wave amplitudes up to 20% (Smith & Mills, 1989; 
van Looij et al., 2004).  
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2, 2, 2 Tribromoethanol 
Avertin (also known as 2, 2, 2 tribromoethanol or tribromoethanol) is a 
non-controlled anesthetic agent used for rodent anesthesia. Tribromoethanol is a 
safe and rapid onset anesthetic with a primary benefit of ease of preparation 
(Maheras & Gow, 2013; Papaioannou & Fox, 1993; Weiss & Zimmermann, 
1999). The main advantages of 2,2,2 tribromoethanol for mouse anesthesia are 
the rapid rate of induction and recovery, the fact that it provides adequate 
surgical plane anesthesia, and has a relative lack of complications (Papaioannou 
& Fox, 1993). The dose range is quite wide with a low risk for overdose and 
lethality. Within the literature, the reported dosage range has been reported to be 
125 to 800 mg/kg with dosages of 200 to 400 mg/kg most commonly 
administered (Cho et al., 2010; Flecknell, 2005; Fish & Meyer, 2008; Hedenqvist 
et al., 2003). In a study of 30 mice administered tribromoethanol with adequate 
surgical anesthesia attained, a death rate of 0% was observed (Cho et al., 2010). 
Similarly, the morbidity and mortality rate of tribromoethanol has been reported to 
be less than 1% (Papaioannou & Fox, 1993).  The main adverse effect reported 
in the literature in association with tribromoethanol is peritoneal inflammation 
(Zeller et al., 1998; Maheras & Gow, 2013). Tribromoethanol was reportedly used 
in the literature for ABR assessment (Zheng et al., 1999; Gow et al., 2004; 
Maheras & Gow, 2013). However, there is no report of validation of 
tribromoethanol compared to rodent ABR anesthetic gold standard of ketamine-
xylazine. 
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Chapter 3: Methods 
Animal Model  
C57BL/6 mice were chosen as the animal model for this study. As 
reviewed in section 2.4, these mice are an accepted model of age-related 
hearing loss. The hearing loss experienced by this strain has been well 
characterized and documented within the literature (Hequembourg & Liberman, 
2001). These mice experience onset of hearing loss around 5-6 months of age 
with near complete deafness by 18 months of age. The mice were housed within 
the RAR facilities at the University of Minnesota under conditions in accordance 
with the NIH guidelines for animal care, PHS Policy on Use of Laboratory 
Animals and the Animal Welfare Act. Care was taken to ensure that discomfort, 
pain, distress and injury were limited in the mice included in this study. Mice were 
given food and drinking water ad libitum. No operative procedures were 
performed on the animals. During ABRs, mice were maintained at a comfortably 
body temperature. Prior to sacrifice, mice were anesthetized with ketamine 
(30mg/kg) and sacrificed by decapitated. This method of sacrifice is consistent 
with the recommendation of the Panel of Euthanasia of American Veterinary 
Medicine Association.   
 
Auditory Brainstem Response (ABR) Testing Technique 
During the ABR testing, the body temperature of each mouse was actively 
maintained at 37°C by placing the animal on a thermal blanket. ABRs were 
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collected by differentially amplifying voltages presented at subdermal needle 
electrodes using a standard vertex positive, ipsilateral mastoid-negative 
montage. ABR recordings, in response to calibrated acoustic signals, were 
obtained in the mice to verify auditory sensitivity to rarefaction clicks and tone 
bursts over a 1 to 32 kHz range. Total tone durations were 1 to 4 ms and 
consisted of Blackman rise/fall times and no plateau.  The polarity of the signals 
were altered during a trial run to identify and reduce signal artifacts and thus to 
minimize the acquisition of spurious signals. The sampling rates were 50 kHz 
and durations were 10 ms for clicks and tone-pips. Five-hundred twelve 
presentations were averaged at each intensity. The gain of the physiological 
amplifier were set to 100,000x for ABRs. Threshold were determined in 5 dB 
steps of decreasing stimulus intensity, until waveforms lose reproducible 
morphology.  
 
Combination Antioxidant 
Given the contribution of oxidative damage to the pathogenesis of 
presbycusis (Figure 7), antioxidants may prevent the onset or progression of 
disease. A number of antioxidants have been reported in the literature to 
attenuate the progression of presbycusis. Some agents previously investigated 
include vitamin E, vitamin C, melatonin, folate, -lipoic acid, L-carnitine, 
rebamipide, and resveratrol (Seidman, 2000; Takumida & Anniko, 2005; Durga et 
al., 2007; Le & Keithley, 2007; Derin et al., 2004; Seidman et al., 2008).  The 
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associated results reported within the literature have been modest. Interestingly, 
most previous studies targeted one or two sites within the oxidative pathway. 
This study endeavored to create a combination antioxidant which targets multiple 
sites within the oxidative pathway.  
To study the potential for preventing oxidative damage in the cochlea as 
related to age-related a combination antioxidant was developed. Figure 7 depicts 
the oxidative pathway within the cochlea. The goal of the combination antioxidant 
agent was to target multiple sites within the oxidative pathway. Six agents were 
chosen to be included with in the combination antioxidant based upon previous 
reports with in the literature or based upon site of action within the oxidative 
pathway. These agents included vitamin B12, folate, vitamin C (ascorbic acid), 
NW-nitro-L-arginine methyl ester (L-NAME), L-cysteine-glutathione mixed 
disulfide (L-CySSG), and ribose-cysteine.  
DNA synthesis and repair is targeted by both vitamin B12 (Figure 8) and 
folate (Figure 9) which may function in the repair of mitochondrial genomic 
deletions. Clinical studies have revealed a correlation between vitamin B12 and 
folate deficiency with the presentation of presbycusis (Houston et al., 1999; Park 
et al., 2006). Additionally, within a clinical trial of 728 aged individuals in the 
Netherlands, folate supplementation administered over 3 years was found to lead 
to a statistically significant (p = 0.02) decrease in age-related threshold shift 
(Durga et al., 2007). These findings, however, were not clinically significant in 
that the difference in threshold shift between the folate and control groups was 
only 0.7 dB (Durga et al., 2007). There, however, have been reports within the 
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literature that challenge the correlation between folate and vitamin B12 with age-
related hearing loss (Berner et al., 2000). 
Vitamin C, also known as ascorbic acid, is a free radical scavenger that 
specifically targets reactive oxygen species (Figure 10). Level 1 evidence of 
ascorbic acid supplementation in Fischer 344 rats revealed an attenuation of age 
related hearing loss of 10-25 dB over the course of 22.5 months of treatment 
(Seidman, 2000). Similarly, clinical trials have revealed an approximate 5 dB 
attenuation of hearing loss at low frequencies with the administration of vitamin C 
and rebamipide over 8 to 52 weeks (Takumida & Anniko, 2005). With the addition 
of -lipoid acid the hearing result was improved at both low and high frequencies. 
Takumida & Anniko, 2009). 
Inducible nitric oxide synthase (iNOS) is a crucial enzyme in the 
production of nitric oxide, a potent reactive nitrogen species (RNS). Within the 
cochlea, nitric oxide is produced by inducible nitric oxide synthase (iNOS). 
Increased expression of iNOS has been demonstrated in the cochlea of aged 
Fischer 344 rats when compared to young rats (Juhn et al., 2002). NOS inhibitors 
may slow or prevent the production of nitric oxide within the labyrinth and its 
subsequent injury. L-NAME is a nitric oxide synthase inhibitor with cochlear 
bioavailability (Figure 11). L-NAME has been demonstrated to be protective 
against noise-induced hearing loss in an animal model and to decrease the 
production of nitric oxide within the perilymph (Diao et al., 2007; Shi et al., 2002). 
L-NAME has been reported to block vestibular hair cell degeneration (Takumida 
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& Anniko, 2000). Thus, L-NAME could potentially prevent the oxidative damage 
created by the presence of nitric oxide in the cochlea in ARHL.  
Glutathione is an important ubiquitous, endogenous antioxidant found in 
the inner ear. Glutathione is a tripeptide consisting of L-cysteine (Cys), L-
glutamic acid (Glu), and glycine (Gly). It is biosynthesized in two-steps catalyzed 
by the enzymes gamma-glutamylcysteine synthetase and glutathione synthetase. 
Reduced levels of glutathione were found in the inner ear of aged Fisher 344 rats 
when compared to young rats (Lautermann et al., 1997). L-CySSG and ribose-
cysteine are both pro-drugs for glutathione (Figure 12 and Figure 13). L-CySSG 
is a mixed disulfide of L-cysteine and L-glutamic acid which has been found to be 
highly effective in protecting the liver from hepatotoxicity in a mouse model of 
oxidative stress induced by reactive oxygen species (Berkeley et al., 2003). 
Ribose-cysteine is a L-cysteine pro-drug which in turn is critical in the 
biosynthesis of GSH.  Ribose-cysteine has been demonstrated to reduce hepatic 
and renal toxicity induced by reactive oxygen species (Lucas et al., 2000; Slitt et 
al., 2005). Neither L-CySSG nor ribose-cysteine has previously been investigated 
in the management of ARHL. 
Together these antioxidants target four specific sites within the oxidative 
pathway: preventing mitochondrial genomic deletions, reducing nitric oxide 
synthase, reducing reactive oxygen species and enhancing glutathione 
production (Figure 14). The antioxidant dosages administered are depicted in 
Table 5. The daily dosages were determined based upon current data regarding 
maximal daily dose and previous reported dosages in the literature for auditory 
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pathologies. The combination antioxidant agent was administered orally via the 
mouse feed. Mice were fed with a milled powder formation of the Teklad NIH-07 
rodent diet. The antioxidants were mixed within the powdered feed. The daily 
dose of antioxidants was mixed with the powdered feed based upon an average 
daily consumption of 5 g of feed daily per 30 g body weight (Bachmanov et al, 
2002).  This rate of food consumption is relatively consistent between the ages of 
3 months and 12 months of age (Starr & Saito, 2012). 
 
Statistical Analysis 
 Standard statistical analysis was performed using Excel software. For 
comparison of threshold means and threshold shift means comparing study 
groups two tailed t-tests were performed with a p<0.05. Additionally, comparing 
the treatment groups and control group Krustal-Wallis analysis of variance 
(ANOVA) was performed to assess for statistically significant differences across 
groups. With p<0.05, post-hoc Tukey method analysis was performed to confirm 
statistical significance as well.  
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Specific Aim 1. To validate 2,2,2 tribromoethanol as an anesthetic 
for mouse auditory brainstem response (ABR) testing using the 
C57BL/6 mouse model.   
 Six C57BL/6 mice were assigned for this portion of the study. Each of the 
mice were assessed bilaterally in a cross-over study design. Mice were assessed 
at age 3 months. In three of the six mice, 2,2,2 tribromoethanol was used for 
ABR assessment on day one followed by ketamine and xylazine on day three. In 
the remaining three of six mice ketamine and xylazine was used for ABR 
assessment on day one followed by 2,2,2 tribromoethanol on day three. The 
following techniques were used for the respective anesthetics. 
Avertin (2, 2, 2, tribromoethanol) was administered intraperitoneal. A dose 
of 50 mg/kg 2, 2, 2, tribromoethanol was utilized. Approximately 5 minutes were 
allowed for the anesthetic effect of the 2, 2, 2 tribromoethanol. The appropriate 
level of anesthesia was confirmed with toe pinch. ABR testing was performed per 
the protocol stated above. Thresholds were recorded bilaterally. Statistical 
analysis was performed comparing the ABR thresholds obtained using ketamine 
and xylazine as an anesthetic versus 2, 2, 2 tribromoethanol as an anesthetic. 
The standard dose of ketamine and xylazine was utilized as a control: 
ketamine 100 mg/kg and xylazine 5 mg/kg. The ketamine and xylazine was 
administered intraperitoneal. Approximately 5 minutes was allowed for the 
anesthetic effect of the ketamine and xylazine. The appropriate level of 
anesthesia was confirmed with toe pinch. ABR testing was then performed as 
reported above. The thresholds were recorded for bilateral assessment.  
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Specific Aim 2. To study the effects of daily, oral administration of a 
combination antioxidant targeting multiple sites within the oxidative 
pathway on the prevention of the onset of age-related hearing loss. 
To assess the impact of oral administration of the combination antioxidant 
on the prevention of onset of age-related hearing loss, C57BL/6 mice were 
randomized to one of two experimental groups: a control group which received 
normal mouse diet and an early treatment group which received initiation of 
antioxidant therapy at 3 months of age (prior to onset of presbycusis as 
documented in the literature). The sample size was determined based on a 
desired power of 0.8, a desired alpha of 0.05 and an estimated size affect delta 
of approximately 1.4 for preliminary data utilizing L-CySSG alone. The size effect 
delta for this study was estimated to be approximately 1.8. Therefore a minimum 
of six animals would need to be assigned to each group for assessment. A total 
of twelve mice were randomized to the control group and twelve mice were 
randomized to early treatment group. The timeline for auditory brainstem 
response testing is presented in Figure 15.  Auditory brainstem response testing 
was performed on the mice in both groups at 3 months of age upon initiation of 
the study. Subsequently auditory brainstem response testing was performed 
every 3 months until the mice were aged 12 months for a total of 9 months of 
serial auditory assessments. All data was recorded within an Excel file. Statistical 
analysis was performed using Microsoft Excel.  
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Specific Aim 3. To study the effects of daily, oral administration of a 
combination antioxidant targeting multiple sites within the oxidative 
pathway on the prevention of the progression of age-related 
hearing loss. 
To assess the impact of oral administration of the combination antioxidant 
on the prevention of the progression of age-related hearing loss, C57BL/6 mice 
were randomized to one of two experimental groups: a control group which 
received normal mouse diet and a delayed treatment group which received 
initiation of antioxidant therapy at 6 months of age (3 months following the onset 
of presbycusis as documented in the literature). The sample size was determined 
as above based on a desired power of 0.8, a desired alpha of 0.05 and an 
estimated to be approximately 1.8. Therefore a minimum of six animals would 
need to be assigned to each group for assessment. A total of twelve mice were 
randomized to the control group and twelve mice were randomized to the 
delayed treatment group. The timeline for auditory brainstem response testing is 
presented in Figure 16.  Auditory brainstem response testing was performed on 
the mice in both groups at 3 months of age upon initiation of the study. 
Additionally, ABR was performed at 6 months of age to confirm onset of age-
related threshold changes. The mice were initiated on antioxidant therapy at 6 
months of age. Subsequently auditory brainstem response testing was performed 
at 9 months and 12 months. All data was recorded within an Excel file. Statistical 
analysis was performed using Microsoft Excel.   
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Chapter 4: Results 
 
Section 4.1: Avertin versus Ketamine/Xylazine for ABR Testing 
A total of 6 mice were selected to assess the impact of Avertin on ABR 
physiology utilizing the technique described above. Within the Avertin then 
ketamine/xylazine group three of three mice survived the complete assessment. 
One mouse did seize and expire after completion of ABR assessment with 
ketamine/xylazine. Within the ketamine/xylazine then Avertin group, one mouse 
expired following ketamine/xylazine administration; therefore, it could not be 
assess in the Avertin condition. Thus, assessments were performed in a total of 5 
mice in a cross-over study design for assessment of Avertin versus 
ketamine/xylazine as anesthetic for ABR. Of note two mortalities among 6 mice 
may be attributed to anesthesia with ketamine and xylazine. There were no 
mortalities attributed to Avertin administration.  
Figure 17 provides the mean ABR thresholds by frequency obtained while 
the mice were anesthetized with ketamine/xylazine (presented in green) and 
mean ABR thresholds by frequency obtained while the mice were anesthetized 
with Avertin (presented in blue). Additionally, the raw ABR threshold data is 
presented in Table 6. A two tailed t-test was performed of the ABR thresholds by 
frequency, overall in total and as mean thresholds. No statistically significant 
difference was noted for Avertin versus ketamine/xylazine (p>0.05). 
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Section 4.2   Early Antioxidant Treatment 
A total of 12 mice were assigned to the control group, and a total of 12 
mice were assigned to the early antioxidant treatment group. Nine mice within 
the control group survived for the duration of the study. The three mice that 
expired during the course of the study were apparently independent of the study 
assessments (i.e. death did not occur within 48 hours of anesthesia for ABR). A 
total of 9 control mice and 12 early antioxidant treatment mice were assess 
longitudinally. 
ABRs were performed at the baseline time period of 3 months (prior to 
onset of antioxidant therapy within the early antioxidant treatment group). The 
ABR threshold data per study animal ear is presented in Figure 18. The control 
mice data are presented in blue, and the early antioxidant treatment mice data 
are presented in yellow. The raw data for most mice within both groups as 
depicted in Figure 18 is relatively similar. This graph does highlight that there 
does appear to be one relative outlier animal (presented as two relative outliers 
plots for right and left ears on the graph) within the early antioxidant treatment 
group with ABR thresholds 10 to 20 dB greater than the mean for either group. 
The mean baseline thresholds by frequency for the control group as compared to 
the early antioxidant treatment group is presented in Figure 19. There was no 
statistically significant difference between the mean thresholds by frequency at 
baseline for the control group versus the early antioxidant treatment group 
(p>0.05 with two-tailed t-test).   
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ABRs were then performed at the 6 month time period. At this time point, 
the early antioxidant treatment group had received 3 months of antioxidant 
therapy. The ABR threshold data per study animal is presented in Figure 20. This 
graph again highlights the presence of two relative outliers within the early 
antioxidant treatment group. Despite the presence of these outliers, a statistically 
significant difference (p < 0.001) was noted between the mean threshold shift 
from the 3 month baseline ABR assessment to the 6 month time point. At the 6 
month time point, the mean ABR threshold shift for the control group was 5.6 dB 
as compared to 0.76 dB within the early antioxidant treatment group. There was, 
however, no statistically significant difference (p > 0.05) on two-tailed t-test when 
comparing the threshold means for the control group as compared to the early 
antioxidant treatment group at 6 months with the exception of at 32 kHz. This is 
partially secondary to the impact of the two relative outliers in the mean threshold 
analysis. With exclusion of these two outlier data points, a statistically significant 
difference was noted between the control ABR mean thresholds and early 
antioxidant treatment ABR mean thresholds at 4 kHz, 16 kHz, and 32 kHz. 
The statistical significance of the early administration of antioxidants in this 
animal model becomes more evident at the 9 month time point. At the 9 month 
ABR assessment time point, the early antioxidant treatment group has received 6 
months of antioxidant therapy. Figure 21 presented the ABR threshold data per 
study animal within the control group and early antioxidant treatment group for 
the 9 month time point. As is apparent by Figure 21, the ABR thresholds for the 
control group overall are greater than that of the early antioxidant treatment 
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group. Figure 22 presents the mean ABR threshold by frequency for the control 
group as compared to the early antioxidant treatment group.  These threshold 
differences were statistically significant at all frequency with a p-value of <0.001. 
On assessment of ABR threshold shift from the 3 month baseline to the 9 month 
time point, the mean overall ABR threshold shift for the control group was 23 dB 
as compared to a 4 dB mean overall ABR threshold shift for the early antioxidant 
treatment group. This difference was statistically significant with a p-value of 
<0.001. On analysis of the mean ABR threshold shift by frequency, the mean 
threshold shift for the control group ranges from 19 to 25 dB as compared to that 
of the early antioxidant treatment group which ranges from 3 to 6 dB. The mean 
threshold shift by frequency as well as associated p-values are presented in 
Table 10. Statistical significance was reached at all frequencies when comparing 
ABR threshold shift from 3 months to 9 months for the control group versus the 
early antioxidant treatment group. 
The impact of early antioxidant therapy become even more substantial on 
evaluation at the 12 month time point of the study. By the 12 month ABR 
assessment time point, the early antioxidant treatment group has received 9 
months of antioxidant therapy. Figure 23 presented the ABR threshold data per 
study animal within the control group and early antioxidant treatment group for 
the 12 month time point. The gap between the ABR thresholds by frequency for 
individual mice in the control group as compare to the early antioxidant treatment 
group as depicted in Figure 23 is quite pronounced (with the exception of the 
outlier data which has been note throughout the study in the early antioxidant 
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treatment group). Figure 24 presents the mean ABR threshold by frequency for 
the control group as compared to the early antioxidant treatment group.  A 
statistical significance of p <0.001 was obtained for all mean threshold 
frequencies when comparing control versus early antioxidant treatment group. 
Statistical significance (p <0.001) was also noted for the mean overall ABR 
threshold shifts from the 3 month baseline assessment to the 12 month ABR 
assessment for the control versus early antioxidant treatment group which was 
found to be 29 dB and 6 dB, respectively. Table 11 depicts the mean ABR 
threshold shift by frequency for the control group versus the early antioxidant 
treatment group at 12 months with associated p-value. The mean threshold shift 
was noted to range from 29 to 38 dB within the control group and 6 to 10 dB in 
the early antioxidant treatment group.  
Finally, the pure tone average over the course of the study was graphically 
evaluated. The pure tone average for each animal was calculated as the sum of 
the threshold at 4 kHz, 8 kHz, 12 kHz, 16 kHz and 32 kHz divided by 5. Figure 26 
graphically depicts the shift in pure tone average by mouse at each of the study 
time points for the control versus early antioxidant treatment groups. This figure 
provides a graphical progression of the impact of early antioxidant therapy on 
ABR thresholds.  
  
59 
 
Section 4.3   Delayed Antioxidant Treatment 
A total of 12 mice were assigned to the control group and a total of 12 
mice were assigned to the control group. Nine mice within the control group and 
nine mice within the delayed treatment group survived for the duration of the 
study. The three mice that expired during the course of the study within each 
group were apparently independent of the study assessment and independent of 
ABR analysis (i.e. death did not occur within 48 hours of anesthesia for ABR). A 
total of 9 control mice and 9 early treatment mice were assess longitudinally. 
ABRs were performed at the baseline time period of 3 months (prior to 
onset of sensorineural hearing loss in the control and delayed antioxidant 
treatment group). The baseline 3 month ABR threshold data per study animal ear 
is presented in Figure 27. The control mice data are presented in blue, and the 
delayed antioxidant treatment mice data are presented in pink. The raw data for 
most mice within both groups as depicted in Figure 27 is similar for both groups. 
The mean ABR baseline thresholds by frequency for the control group as 
compared to the delayed antioxidant treatment group is presented in Figure 28. 
There was no statistically significant difference between the mean thresholds by 
frequency at baseline for the control group versus the early treatment group 
(p>0.05 with two-tailed t-test).   
ABRs were then performed at the 6 month time period to confirm onset of 
sensorineural hearing loss in the delayed antioxidant treatment group. The ABR 
threshold data per study animal is presented in Figure 29. As expected, the ABR 
thresholds for the control group and the delayed antioxidant treatment groups are 
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similar at the 6 month time period as the delayed antioxidant treatment group has 
yet to receive antioxidant therapy. Figure 30 provides the mean ABR thresholds 
by frequency for the control group and the delayed antioxidant treatment groups. 
No statistically significant difference is noted on two tailed t-test between the 
overall thresholds or the threshold by frequency for these two groups (p >0.05). 
Following the 6 months ABR assessment, the mice within the delayed antioxidant 
treatment group were initiated on the combination antioxidant therapy. 
ABR assessment was then performed 3 months following initiation of 
antioxidant therapy within the delayed antioxidant treatment group at the 9 month 
time point. Figure 31 presented the ABR threshold data per study animal within 
the control group and delayed antioxidant treatment group for the 9 month time 
point. As is apparent by Figure 31, the ABR thresholds for the control group have 
progressed over the course of 3 months to be overall greater than that of the 
delayed antioxidant treatment group with only 3 months of antioxidant therapy 
even after onset of hearing loss in the delayed antioxidant treatment group. 
Figure 32 presents the mean ABR threshold by frequency for the control group 
as compared to the delayed antioxidant treatment group.  These threshold 
differences were statistically significant at all frequency with a p-value of <0.001. 
On assessment of ABR threshold shift from the 3 month baseline to the 9 month 
time point, the mean overall ABR threshold shift for the control group was 23 dB 
as compared to a 4 dB mean overall ABR threshold shift for the delayed 
antioxidant treatment group. This difference was statistically significant with a p-
value of <0.001. On analysis of the mean ABR threshold shift by frequency, the 
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mean threshold shift for the control group ranges from 19 to 25 dB as compared 
to that of the delayed antioxidant treatment group which ranges from 2 to 6 dB. 
The mean threshold shift by frequency as well as associated p-values are 
presented in Table 13. Statistical significance was reached at all frequencies 
when comparing ABR threshold shift from 3 months to 9 months for the control 
group versus the delayed antioxidant treatment group. 
The threshold differences between the control and delayed antioxidant 
treatment groups became more marked at the 12 month time point of the study. 
By the 12 month ABR assessment time point, the delayed antioxidant treatment 
group has received 6 months of antioxidant therapy. Figure 33 presents the ABR 
threshold data per study animal within the control group and delayed antioxidant 
treatment group for the 12 month time point. The chiasm between the ABR 
thresholds by frequency between individual mice in the control group as compare 
to the delayed antioxidant treatment group as depicted in Figure 23 is more 
pronounced that that observed at the 9 month time point. Figure 34 presents the 
mean ABR threshold by frequency for the control group as compared to the 
delayed antioxidant treatment group at 12 months.  A statistical significance of p 
<0.001 was obtained for all mean threshold frequencies when comparing control 
versus delayed antioxidant treatment group. Statistical significance (p <0.001) 
was also noted for the mean overall ABR threshold shifts from the 3 month 
baseline assessment to the 12 month ABR assessment for the control versus 
delayed antioxidant treatment group which was found to be 29 dB and 9 dB, 
respectively. Table 14 depicts the mean ABR threshold shift by frequency for the 
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control group versus the delayed antioxidant treatment group at 12 months with 
associated p-value. The mean threshold shift was noted to range from 29 to 38 
dB within the control group and 6 to 11 dB in the delayed antioxidant treatment 
group.  
Finally, the pure tone average over the course of the study was graphically 
represented. The pure tone average for each animal was calculated as the sum 
of the threshold at 4 kHz, 8 kHz, 12 kHz, 16 kHz and 32 kHz divided by 5. Figure 
36 graphically depicts the shift in pure tone average by mouse at each of the 
study time points for the control versus delayed antioxidant treatment groups. 
This figure provides a graphical progression of the impact of delayed antioxidant 
therapy on ABR thresholds.  
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Chapter 5: Discussion 
 
Section 5.1: Summary of Findings 
 Auditory brainstem response testing has been used extensively in the 
auditory physiology literature as a means of characterizing hearing within various 
strains of mice and as a means of assessing the impact of various therapeutic 
modalities on hearing in animal models. Traditionally, within the mouse model 
ketamine and xylazine have been used as a mouse anesthetic as it has been 
characterized to produce consistently reliable results with minimal morbidity for 
single assessment with only minor changes noted in wave latency and amplitude 
(Smith & Mills, 1989; Huang et al., 1995; Miller et al., 1998; Ou et al., 2000; Jero 
et al., 2001; Henry 2002; van Looij et al., 2004). However, with multiple dosages 
administered, a significant mortality rate for ketamine and xylazine has been 
documented in the literature (Arras et al., 2001). Within specific aim 1 of this 
study, Avertin was compared with the gold standard ketamine and xylazine for 
anesthetic during auditory brainstem response testing in a mouse model. Avertin 
was found to have equivalent anesthetic properties without noted significant 
alteration in auditory brainstem responses in an animal model. The rate of 
mortality associated with these mice was noted to be decreased with Avertin as 
compared to ketamine and xylazine with 2 deaths attributable to ketamine and 
xylazine versus none attributed to Avertin. Similar results were recently reported 
by Maheras and Gow regarding the use of Avertin alone and Avertin plus chloral 
hydrate for auditory brainstem response testing in mice. Although necropsy was 
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not performed in this current study for specific aim 1, necropsy was performed by 
Maheras and Gow which revealed no significant intraperitoneal changes with the 
exception of mild inflammation following intraperitoneal injection of Avertin.  
The combination antioxidant was investigated in specific aims 2 and 3 to 
determine whether this combination antioxidant has the potential for preventing 
age related threshold shifts in an animal model (specific aim 2) and/or treat age 
related threshold shifts in an animal model (specific aim 3). With both early 
treatment and delayed treatment, a statistically significant difference was noted in 
ABR threshold shift. The combination antioxidant which was designed to target 4 
specific sites within the oxidative pathway appears to have prevented age related 
threshold shifts within the animal model of the C57BL6 mouse. Amongst the 
study groups there were no apparent toxicities or mortalities that can be 
attributed to the administration of the oral antioxidant.  
These findings are suggestive of the potential for developing a 
combination antioxidant agent which targets multiple sites within the oxidative 
pathway for treatment or prevention of age-related hearing loss in the clinical 
setting. However, further study would be necessary to make the transition from 
bench-top to bedside. The data presented within this document has been 
published by Otolaryngology – Head and Neck Surgery (Appendix A), and has 
since been cited by various authors internationally (Appendix B). There are a 
number of limitations within this study that would need to be evaluated further via 
investigation or review of the literature prior to embarking upon clinical trials. 
However, these results are promising in the potential for developing a drug 
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therapy for the treatment and/or prevention of age-related hearing loss in a 
clinical setting which will become an increasing public health concern. 
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Section 5.2: Study Limitation 
 As with any study, there are a number of limitations which must be 
acknowledged. First, although the sample size is small, it is adequate to attain 
statistically significant analysis. However, the power of the study would be 
increased with a larger sample size. Second, although the C57BL6 has been a 
well-established model commonly used for the investigation of age-related 
hearing loss, some controversy has arisen within recent literature regarding the 
pathogenesis of age-related thresholds changes in C57BL6 and its association 
with the pathogenesis of age-related hearing loss in the clinical setting. Within 
the clinical setting, age-related hearing loss is believed to have a genetic 
component, but it is believed to largely present as a function of various other 
environmental and physiological factors (DeStefano et al., 2003; Kane et al., 
2012). However, within the C57BL6 mouse model a mutation in the ahl gene at 
the Cdh23ahl allele has been established to be the pathophysiologic agent for 
accelerated hearing loss. Histological and immunohistological assessment of the 
C57BL6 mice with aging has been noted to parallel changes noted in 
presbycusis. Third, physiological data is provided without histological or 
immunohistological sections. This was unfortunately due to the lack of availability 
of these services at the time of sacrifice. Fourth, the goal of the study was to 
identify an agent that targets multiple sites within the oxidative pathway; 
however, previously within the age-related hearing loss literature, each of these 
agents had not individually be examined thoroughly, namely ribose cysteine and 
L-NAME. Fifth, although no deaths or mortality within this study can be attributed 
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to the administration or consumption of the combination antioxidant agent, formal 
toxicity analysis was not performed. The evidence suggests that the combination 
antioxidant did not produce any toxic effects in that within the group that received 
the longest duration of treatment, there were no deaths over the 6 month 
treatment period while 3 deaths respectively were experienced in the control and 
delayed treatment groups. However, toxicity of the combination antioxidant was 
not performed. Individual toxicity data for the agents included in the combination 
antioxidant were reviewed from the literature and utilized for designation of 
dosage within the combination agent. A detailed review is provided in Appendix 
C. 
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Section 5.3: Future Studies 
In light of the limitations within this current study and to further investigate 
the potential of this combination antioxidant as a potential clinical therapy for the 
prevention or treatment of age-related hearing loss, various further studies are of 
interest. First, given the concern regarding the pathogenesis of accelerated age-
related threshold shifts in the C57BL6 mouse model, the study could be repeated 
within an animal model lacking the Cdh23ahl allele mutation of the ahl gene. 
Alternatively, toxicity analysis could be performed within any animal model to 
assess for potential toxicities in association with this combination high dosage 
antioxidant followed by moving to clinical trials if no significant toxicity is 
established.  
It may also be of interest to investigate the two drug components not 
previously investigated for their potential impact on age-related hearing loss. 
Theoretically it is possible, but less likely, that the decrease in threshold shift 
noted within this study with age is attributable to one of these single agents not 
previously investigated. This theory is contrary to the premise of this study that 
targeting multiple sites within the oxidative pathway prevents therapeutic 
resistance and activation of alternative pathways within the oxidative system. A 
potential future study would investigate each of these agents individually as well 
as in various permutations as combination agents to assess for the optimal agent 
to prevent or treat age-related threshold shift. 
This current study focuses on electrophysiologic data to support the 
potential impact of this combination antioxidant on the progression of age-related 
69 
 
changes within the cochlea. Further study including histological analysis of 
characteristic changes with aging with the cochlea or the lack of such changes 
with the combination antioxidant therapy would further support the 
electrophysiological findings. Similarly, immunohistochemical analysis for 
changes in various protein and enzymatic expression that is characteristic of 
cochlear aging (i.e. connexin, Na+-K+-ATPase, carbonic anhydrase and creatine 
kinase expression). 
Additionally, given the fact that this combination antioxidant agent targets 
the oxidative-reductive pathway within the inner ear, this agent could be 
investigated for the prevention or treatment of alternative disease processes with 
a similar mechanism of injury of oxidative stress and damage. One major 
concern particularly within the military and police force is the associated 
occupational hazard of noise induce hearing loss. Chronic administration of a 
combination antioxidant could prove beneficial in attenuating or preventing the 
commonly associated noise induced threshold shifts and association tinnitus 
which is most bothersome to patients within this population. Similarly, 
chemotherapy and radiation therapy are believed to incite sensorineural hearing 
loss through mechanisms partially mediated by oxidative damage. This 
combination agent could prove instrumental in preventing ototoxicity in 
chemotherapy and radiation therapy which could greatly impact the landscape of 
cancer treatment globally. Finally, intratympanic administration of this agent 
could be investigated as an alternative means of drug delivery. 
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Section 5.4: Potential Clinical Application 
Although this represents a single animal case-controlled trial of a 
combination antioxidant which targets 4 main sites within the oxidative pathway, 
the data presented within this study provides promising results for the potential of 
the development of a medical therapy for the treatment and prevention of age-
related hearing loss clinically. This combination agent, because of its 
composition, could be administered in a number of formats including as a vitamin 
tablet (akin to Ocuvite for vision health with aging), as a gummy or chewable, or 
in a beverage form as a dietary supplement for the prevention or treatment of 
age-related hearing loss. Additionally, with investigation of it use in alternative 
disease processes mediated by oxidative damage, this agent potentially could be 
used to prevent or treat various forms of oxidative stress mediated cochlear 
damage with associated hearing loss.  
Interestingly, with regard to the United States Food and Drug 
Administration (FDA), relative to vitamins and natural substances, the FDA does 
not require nor does it provide approval for vitamins and natural substances in 
claims of treatment for disease processes. The FDA only certifies safety of 
vitamins and natural substances, but does not require efficacy testing, nor does it 
support claims of efficacy for treatment. Thus, there are relatively few barriers 
from a regulatory perspective in bringing a combination antioxidant such as the 
one described within this manuscript to market for clinical usage aside from 
investigation of agent safety.  
 
Age of Population Prevalence
65 years of age or greater 35 to 50%
75 years of age or greater 40 to 65%
85 years of age or greater over 80%
100 years of age or greater approximately 90%
Table 1. Prevalence of Presbycusis with Increasing Age
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NIOSH OSHA
8 85 dB 90 dB
6 86 dB 92 dB
4 88 dB 95 dB
3 89 dB 97 dB
2 90 dB 100 dB
1.5 92 dB 102 dB
1 94 dB 105 dB
0.5 97 dB 110 dB
0.25 100 dB 115 dB*
0 112 dB
Permissible Noise Level Exposure
Sound LevelHours per 
day
Table 2. National Institute for Occupational Safety and Health (NIOSH) 
and Occupational Safety and Health Administration (OSHA) 
Recommended Permissible Noise Exposure Levels
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Stimulus Sound Level
Rustling leaves 20 dB
Whisper at 6 feet 30 dB
Residential area at night 40 dB
Quiet office 50 dB
Normal Conversation 60 - 65 dB
Hair dryer 60-95 dB
Car noise 70 dB
Traditional vacuum cleaner 70 dB
Door bell 80 dB
Blender 80-90 dB
City Traffic 85 dB
Subway 90 - 115 dB
Hand Drill 95 - 100 dB
Gas lawnmower 95 - 110 dB
Snowblower 95 - 110 dB
Snowmobile 100 dB
Motorcycle 100 dB
Chain saw 110 dB
Sandblaster 115 dB
Maximum volume ear buds 85 - 115 dB
Ambulance siren 120 dB
Loud Concert 100 - 125 dB
Pneumatic riveter 125 dB
Jet engine 140 dB
0.22 Caliber riffle 145 dB
Fireworks 150 dB
12 Gauge Shotgun 165 dB
0.357 Caliber revolver 170 - 175 dB
Environmental Sounds
Table 3. Commonly and Less Commonly Encountered Environmental 
Sounds
73
Factor Exposures
Environmental: Noise
Low socioeconomic status
Chemical Exposures: Toluene
Trichloroethylene
Styrene
Otologic Disease: Otosclerosis
Chronic otomastoiditis
Temporal bone trauma
Meniere's
Medications: Aminoglycosides
Platinum-based chemotherapeutic agents
Loop diuretics
phosphodiesterase type 5 inhibitors 
Salicylate
Habitual: Tobacco*
Alcohol abuse*
Systemic Disease: Renal Failure
Diabetes
Cardiovascular disease
Immunodeficiency
Protective Factors: Estrogen
High bone mineral density
Caloric Restriction*
Aldosterone
*conflicting reports in the literature
     
 
Table 4.  Factors Contributing to Presbycusis
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Antioxidant Daily Dose
Vitamin B12 80 mcg/kg 
Folate 100 mcg/kg 
Ascorbic Acid 200 mg/kg 
L-NAME 250 mg/kg 
L-CySSG 200 mg/kg 
Ribose-cysteine 200 mg/kg 
Table 5. Combination Antioxidant Component Daily Dosage
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Table 6. Avertin versus Ketamine/Xylazine Case-Control Raw ABR Data
Avertin ABR Ketamine/Xylazine ABR
Click 1kHz 2kHz 4kHz 8kHZ 12kHz 16kHz 32kHz Click 1kHz 2kHz 4kHz 8kHZ 12kHz 16kHz 32kHz
1
R 30 75 70 40 10 10 15 30 30 75 70 35 10 10 15 30
L 35 75 70 45 15 20 20 40 35 75 70 50 15 20 20 35
2
R 30 70 70 30 15 15 15 20 30 70 70 30 10 15 20 20
L 30 75 70 40 15 15 20 25 30 75 70 40 10 15 20 25
3
R 35 75 70 50 20 15 30 40 35 75 70 50 20 15 30 40
L 30 70 60 40 15 15 30 40 30 70 60 40 15 15 30 40
4
R 30 80 70 35 15 10 20 25 30 80 70 40 15 10 20 30
L 30 80 70 30 10 10 20 40 30 80 70 30 10 15 20 35
5
R 30 80 75 40 10 10 20 30 30 80 75 40 10 10 20 30
L 30 80 75 40 10 10 20 30 30 80 75 40 10 10 20 30
7
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ID # Side
3 months ABR (dB) 6 months ABR (dB) 9 months ABR (dB) 12 months ABR (dB)
4kHz 8kHz 12kHz 16kHz 32kHz 4kHz 8kHZ 12kHz 16kHz 32kHz 4kHz 8kHZ 12kHz 16kHz 32kHz 4kHz 8kHZ 12kHz 16kHz 32kHz
Control 23 R 20 10 10 20 30 40 20 20 30 40 60 40 40 55 60 70 50 60 60 70
Control 23 L 35 15 15 20 40 40 20 20 30 40 60 40 40 50 60 70 50 50 60 70
Control 24 R 35 10 10 15 35 50 20 20 30 50 60 40 40 45 60 70 50 55 60 65
Control 24 L 30 15 15 20 35 40 15 15 20 40 55 30 40 50 60 60 45 55 60 70
Control 25 R 40 10 15 15 30 50 20 20 30 50 60 40 40 50 60 70 50 60 65 70
Control 25 L 30 10 10 15 30 40 15 20 30 40 50 30 30 40 60 60 50 50 55 70
Control 26 R 40 10 10 20 40 40 20 15 25 40 55 40 40 50 60 70 60 60 65 70
Control 26 L 40 20 10 20 40 40 20 15 20 40 50 40 30 45 55 65 55 40 50 70
Control 28 R 50 20 20 30 40 50 20 20 30 40 60 40 40 50 60 70 50 55 60 65
Control 28 L 40 15 15 20 35 50 15 20 30 40 55 40 40 50 60 70 55 50 60 70
Control 31 R 40 15 20 25 30 40 20 20 30 40 60 40 35 40 55 70 55 50 50 65
Control 31 L 40 15 15 25 30 40 20 20 30 40 50 40 35 40 60 60 50 45 55 65
Control 32 R 40 15 20 25 55 60 20 30 40 60 70 40 40 50 70 80 55 60 65 75
Control 32 L 45 15 15 20 40 45 15 15 20 40 60 35 30 40 60 70 50 40 50 70
Control 43 R 30 15 15 20 30 40 15 20 30 50 60 40 40 40 70 70 50 55 50 75
Control 43 L 50 15 15 20 30 50 20 15 30 50 55 45 40 45 70 60 60 55 50 75
Control 44 R 50 15 15 30 40 50 20 20 30 50 60 40 35 45 60 70 55 40 60 70
Control 44 L 50 15 15 30 40 50 20 15 30 40 60 40 40 40 65 70 50 50 55 75
Table 7. Control Cohort Longitudinal Raw ABR
7
7
ID # Side
3 months ABR (dB) 6 months ABR (dB) 9 months ABR (dB) 12 months ABR (dB)
4kHz 8kHz 12kHz 16kHz 32kHz 4kHz 8kHZ 12kHz 16kHz 32kHz 4kHz 8kHZ 12kHz 16kHz 32kHz 4kHz 8kHZ 12kHz 16kHz 32kHz
Early  56 R 60 30 30 40 30 60 30 30 40 30 65 40 30 40 45 70 40 40 40 50
Early  56 L 65 40 40 60 70 65 40 40 60 70 70 40 40 60 70 70 40 40 60 70
Early  57 R 30 15 15 20 30 30 15 15 20 30 40 20 20 30 30 50 20 25 30 35
Early  57 L 30 15 15 20 25 30 15 15 20 30 35 20 15 20 35 35 20 20 30 40
Early  60 R 35 25 20 25 30 35 25 20 25 30 40 30 30 30 40 40 30 30 40 45
Early  60 L 40 10 15 20 25 40 15 20 20 30 40 15 20 25 30 40 20 20 30 35
Early  71 R 40 20 20 30 35 40 20 20 30 35 40 20 20 30 40 40 20 20 30 40
Early  71 L 40 20 20 30 35 40 20 20 30 35 50 20 25 30 40 50 25 30 35 40
Early  75 R 30 15 20 20 25 30 15 20 20 30 30 20 20 25 30 30 20 20 30 35
Early  75 L 30 15 15 20 25 30 15 20 20 30 30 15 20 30 35 30 15 20 30 35
Early  62 R 50 20 20 25 30 50 20 20 25 30 50 20 20 30 35 55 20 25 35 40
Early  62 L 50 20 15 25 30 50 20 20 25 30 55 20 20 30 40 55 30 25 35 40
Early  65 R 30 10 10 15 30 35 15 15 20 30 40 15 20 20 35 40 20 20 25 40
Early  65 L 30 10 10 15 30 35 15 15 20 30 40 20 15 20 35 40 20 20 20 40
Early  66 R 40 15 10 20 30 40 15 10 20 30 45 15 15 20 30 50 20 15 20 35
Early  66 L 40 15 15 20 30 40 15 15 20 30 50 20 15 25 35 50 20 20 30 40
Early  67 R 40 20 20 30 40 40 20 20 30 40 40 20 20 35 50 45 20 20 40 50
Early  67 L 30 15 15 20 40 30 15 15 20 40 30 15 20 25 40 35 29 25 30 50
Early  68 R 30 10 10 20 30 35 10 10 20 30 40 15 15 30 35 45 20 20 30 40
Early  68 L 50 15 10 20 25 50 15 10 20 25 50 20 15 20 30 50 30 20 30 40
Early  69 R 30 20 20 20 35 30 20 20 20 35 30 20 20 40 40 35 20 25 40 45
Early  69 L 40 15 20 20 35 40 15 20 20 35 50 20 25 40 45 50 20 30 40 50
Early  70 R 50 20 20 30 40 50 20 20 30 40 50 20 30 30 45 55 25 30 30 50
Early  70 L 40 10 15 20 30 40 15 15 20 30 40 15 20 20 30 40 20 20 25 40
Table 8. Early Treatment Cohort Longitudinal Raw ABR
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Frequency 
(kHz)
Control 
Mean 
Threshold 
(dB)
Early Treatment 
Early Treatment Less 
Outliers
Mean 
Threshold (dB)
p - value
Mean 
Threshold (dB)
p - value
4 45 40 0.06 38 0.002
8 19 18 0.85 17 0.06
12 19 19 0.83 17 0.12
16 29 25 0.12 23 <0.001
32 44 34 <0.001 32 <0.001
Table 9. 6 Month Control versus Early Antioxidant Treatment Impact of Outliers
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Table 10. 9 Month Mean ABR Threshold Shift by Frequency Control versus 
Early Antioxidant Treatment Group
Frequency (kHz) Control Early Treatment p - value
4 19 4 <0.001 
8 25 3 <0.001
12 23 4 <0.001
16 24 5 <0.001
32 25 6 <0.001
8
0
Table 11. 12 Month Mean ABR Threshold Shift by Frequency Control versus 
Early Antioxidant Treatment Group
Frequency (kHz) Control Early Treatment p - value
4 29 6 <0.001 
8 38 6 <0.001
12 37 7 <0.001
16 36 8 <0.001
32 34 10 <0.001
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Table 12. Delayed Antioxidant Treatment Cohort Longitudinal Raw ABR
ID # Side
3 months ABR (dB) 6 months ABR (dB) 9 months ABR (dB) 12 months ABR (dB)
4kHz 8kHz 12kHz 16kHz 32kHz 4kHz 8kHZ 12kHz 16kHz 32kHz 4kHz 8kHZ 12kHz 16kHz 32kHz 4kHz 8kHZ 12kHz 16kHz 32kHz
Delayed 33 R 65 30 30 40 50 70 30 30 40 50 60 30 30 40 50 60 30 35 40 60
Delayed 33 L 50 25 35 50 65 50 30 30 50 60 50 30 30 50 60 55 30 30 55 60
Delayed 47 R 40 20 20 30 40 40 20 20 30 40 40 25 15 30 50 40 30 20 30 55
Delayed 47 L 40 20 20 30 40 40 20 20 30 40 50 20 20 20 50 50 30 20 25 60
Delayed 48 R 30 15 15 20 25 30 20 20 30 35 35 20 20 30 50 40 25 30 40 50
Delayed 48 L 30 15 10 15 20 30 20 15 20 30 30 25 20 20 50 35 30 25 30 50
Delayed 41 R 50 15 20 20 40 50 20 20 30 40 50 20 15 25 40 50 20 20 30 40
Delayed 41 L 50 20 15 20 40 50 20 20 30 40 50 20 20 20 40 55 30 20 30 45
Delayed 42 R 40 20 20 30 50 40 30 30 40 50 40 20 20 30 40 50 30 20 30 40
Delayed 42 L 40 20 25 30 40 40 30 30 40 50 40 30 20 30 50 45 40 30 35 50
Delayed 52 R 50 15 20 20 30 50 20 20 30 40 50 20 30 30 50 50 30 30 40 50
Delayed 52 L 40 10 10 20 30 40 15 20 30 40 50 20 20 20 35 55 30 30 35 40
Delayed 54 R 40 20 15 30 40 40 20 20 30 40 40 20 20 30 40 45 30 30 40 55
Delayed 54 L 30 15 15 30 45 40 20 20 30 50 45 20 20 35 50 50 30 30 40 50
Delayed 55 R 30 10 10 15 20 40 20 15 20 30 40 20 20 20 35 45 20 20 30 40
Delayed 55 L 50 15 20 25 35 50 20 20 30 40 50 20 20 30 35 50 20 30 35 40
Delayed 45 R 60 15 15 30 40 60 20 20 30 40 60 20 20 30 40 65 30 30 40 50
Delayed 45 L 50 15 15 25 40 50 20 20 30 40 50 20 20 30 40 55 30 30 40 55
8
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Frequency (kHz) Control
Delayed 
Treatment 
p - value
4 19 3 <0.001 
8 25 5 <0.001
12 23 3 <0.001
16 24 2 <0.001
32 25 6 <0.001
Table 13. 9 Month Mean ABR Threshold Shift by Frequency Control versus 
Delayed Antioxidant Treatment Group
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Table 14. 12 Month Mean ABR Threshold Shift by Frequency Control versus 
Delayed Antioxidant Treatment Group
Frequency (kHz) Control
Delayed 
Treatment 
p - value
4 29 6 <0.001 
8 38 11 <0.001
12 37 7 <0.001
16 36 8 <0.001
32 34 11 <0.001
8
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Figure 1. Pure Tone Audiogram Characteristic of Presbycusis
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Figure 2. WHO 2012 Estimates of Disabling Hearing Loss in Individuals 65 Years 
and Over by Region
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Figure 3. Sensory Presbycusis
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Figure 4. Neural Presbycusis
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Figure 5. Metabolic Presbycusis
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Figure 6. Mechanical Presbycusis
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Figure 7. Oxidative Pathway within the Cochlea
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Figure 8. Vitamin B12 Site of Action within the Oxidative Pathway
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Figure 9. Folate Site of Action within the Oxidative Pathway
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Figure 10. Ascorbic Acid Site of Action within the Oxidative Pathway
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Figure 11. L-NAME Site of Action within the Oxidative Pathway
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Figure 12. L-CySSG Site of Action within the Oxidative Pathway
9
6
Oxidative Damage to:
Proteins
Lipids
mtDNA
OH-
O2
-H2O2H2O
GSHGSSG
H2O O2
Cell Death
Fe2+/3+
ONOO-
L-Arg
NO
NOS
SODGSH Peroxidase
Catalase
NADP+ NADPH
O2
NADH Oxidase
NADPH
NADP+
GSH Reductase RS
L-Arg = L-Arginine
NOS= Nitric oxide synthase
NO = Nitric oxide
ONOO- = Peroxynitrite
SOD = Superoxide dismutase
GSH = Glutathione
GSSG = Glutations disulfide
mtDNA = Mitochondrial DNA
Figure 13. Ribose-Cysteine Site of Action within the Oxidative Pathway
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Figure 14. Combination Antioxidant Therapy Site of Action within the Oxidative Pathway
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Figure 15. Specific Aim 2: Timeline for Early Antioxidant Treatment Protocol (in Months)
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Figure 16. Specific Aim 3: Timeline for Delayed Antioxidant Treatment Protocol 
(in Months)
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Figure 17. Specific Aim 1: 2,2,2 Tribromoethanol versus Ketamine/Xylazine for ABR 
in C57BL/6 Mice
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Figure 18. Specific Aim 2: 3 Month Baseline Individual ABR Data Early 
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Figure 19. Specific Aim 2: 3 Month Baseline Mean ABR Thresholds Early 
Antioxidant Treatment Versus Control Groups
Th
re
sh
o
ld
 (
d
B
)
Frequency (kHz)
1
0
3
010
20
30
40
50
60
70
4 8 12 16 32
Figure 20. Specific Aim 2: 6 Month Individual ABR Data Early Antioxidant
Treatment Versus Control Groups
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Figure 21. Specific Aim 2: 9 Month Individual ABR Data Early Antioxidant 
Treatment Versus Control Groups
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Figure 22. Specific Aim 2: 9 Month Mean ABR Thresholds Early Antioxidant 
Treatment Versus Control Groups
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Figure 23. Specific Aim 2: 12 Month Individual ABR Data Early Antioxidant 
Treatment Versus Control Groups
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Figure 24. Specific Aim 2: 12 Month Mean ABR Thresholds Early Antioxidant 
Treatment Versus Control Groups
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Figure 25. Specific Aim 2: 12 Month Mean ABR Threshold Shifts Early 
Antioxidant Treatment Versus Control Groups
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Figure 26. Specific Aim 2: Individual Pure Tone Averages Early Antioxidant 
Treatment Versus Control Groups
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Figure 27. Specific Aim 3: 3 Month Baseline Individual ABR Data Delayed 
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Figure 28. Specific Aim 3: 3 Month Baseline Mean ABR Thresholds            
Delayed Versus Control Groups
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Figure 30. Specific Aim 3: 6 Month Mean ABR Thresholds Delayed Antioxidant 
Treatment Versus Control Groups
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Figure 31. Specific Aim 3: 9 Month Individual ABR Data Delayed Versus 
Control Groups
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Figure 32. Specific Aim 3: 9 Month Mean ABR Thresholds Delayed Versus 
Control Groups
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Figure 33. Specific Aim 3: 12 Month Individual ABR Data Delayed Versus  
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Figure 34. Specific Aim 3: 12 Month Mean ABR Thresholds Delayed Versus 
Control Groups
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Figure 35. Specific Aim 3: 12 Month Mean ABR Threshold Shifts Delayed 
Versus Control Groups
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Appendix C 
 
 A variable amount of data is available regarding effective dose, tolerable 
upper intake level (UL), and toxicity for the antioxidants including within the 
combination antioxidant. The antioxidants which have been studied most 
extensively and have the greatest degree of available data include folate, vitamin 
B12 and vitamin C. In fact, these three antioxidant have established reference 
daily intake (RDI) or daily values (DV) for recommended intake (folate 400 mcg, 
vitamin C 60 mg, and vitamin B12 6 mcg) (Food and Drug Administration, 2015). 
However, the tolerable upper intake level for each of these antioxidants is 
significantly higher. Less extensive studies have been conducted to evaluate 
these characteristic for L-NAME, ribose cysteine and L-CySSG. A synopsis of the 
currently available data is presented within this appendix. 
 
Vitamin C 
 According to the Institute of Medicine Dietary Reference Intakes for 
Vitamin C, Vitamin E, Selenium, and Carotenoids (2000), the daily intake of 
vitamin C required to provide antioxidant protection is 90 mg/day for adult men 
and 75 mg/day for adult women based on intake necessary to maintain near-
maximal neutrophil concentration with minimal urinary excretion of ascorbic acid. 
For smokers, the required daily intake of vitamin C is increased by 35 mg/day. 
Ascorbic acid or vitamin C functions as a potent antioxidant scavenger of reactive 
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oxygen species, but also functions as an antioxidant for some reactive nitrogen 
species, in collagen synthesis, as well as in synthesis and modulation of 
hormonal components of the nervous system (Institute of Medicine, 2000). The 
positive effect range for vitamin C reportedly ranges from 50 to 2,000 mg/day. 
Reviews of high vitamin C intake indicates low toxicity (Johnston, 1999). 
The tolerable upper intake level (UL) for vitamin C in adults is set at 2 g per day 
with associated adverse effects of osmotic diarrhea and gastrointestinal 
disturbance noted above this level (Kallner et al., 1979). Typically, adverse 
effects begin to present with intakes of greater than 3 g/day. This is likely due to 
limitations of saturable intestinal absorption and renal tubular resorption; thus 
overload of ascorbic acid is unlikely in humans (Blanchard et al, 1997; Levine et 
al., 1996). The most common adverse effects noted with high doses of vitamin C 
are nausea, abdominal cramps, and diarrhea (Hoffer, 1971). However, additional 
potential adverse effects include increased oxalate excretion, renal stones, 
increased uric acid excretion, pro-oxidant effects, systemic conditioning 
(“rebound scurvy”), increased iron absorption leading to iron overload, reduced 
vitamin B12 and copper status, increased oxygen demand, and erosion of dental 
enamel (Herbert & Jacob, 1974; Hornig & Moser, 1981; McLaran et al., 1982; 
Rivers, 1987; Levine et al., 1996a; Wandzilak et al. 1994; Institute of Medicine, 
2000). 
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Folate 
According to the Institute of Medicine Dietary Dietary Reference Intake for 
Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, 
Biotin, and Choline (1998), the recommended daily allowance of folate is 400 
mcg/day. Folate functions in deoxyribonucleic acid (DNA) synthesis (which 
depends on a folate coenzyme for pyrimidine nucleotide biosynthesis), purine 
synthesis, generation of formate in the formate pool, and amino acid 
interconversion. The bioavailability of folic acid is 85 to 100% for oral 
consumption (Gregory, 1997; Pfeiffer et al., 1997). The UL for folate is 1,000 
mcg/day (Institute of Medicine, 1998). Various adverse effects are noted in 
association with high doses of folic acid including masking vitamin B12 deficiency 
and neuropathy in individuals with B12-deficiency (Chodos & Ross, 1951; Spies 
et al, 1948; Wagley, 1948; Institute of Medicine, 1998). Additionally, mental 
status changes, sleep disturbance, gastrointestinal effects have been reported 
(Hunter et al., 1970). However, studies using comparable higher doses failed to 
confirm the previously stated adverse effects (Gibberd et al., 1970; Hellstrom, 
1971; Richens, 1971; Sheehy 1973; Suarez et al. 1947). In fact, extensive 
studies folate supplementation in females of reproductive age for prevention of 
neural tube defects have revealed folate to be safe at high doses in a cohort of 
100 females over 7 to 10 years (Holmes-Siedle et al. 1992). These findings have 
been confirmed with two extensive large scale randomized controlled trials of 
folate supplementation in 4,753 and 5,502 women respectively with no adverse 
effect (Czeizel and Dudas, 1992; Czeizel et al.,1994). 
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Vitamin B12 
According to the Institute of Medicine Dietary Dietary Reference Intake for 
Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, 
Biotin, and Choline (1998), the recommended daily allowance of vitamin B12 is 
2.4 mcg/day. However, there is insufficient evidence to set a UL because there is 
no evidence that excess B12 intake causes adverse effect. “No adverse effects 
have been associated with excess B12 intake from food or supplements in 
healthy individuals” (Institute of Medicine, 1998). There is risk for patients with 
Leber optic atrophy. Vitamin B12 administration in patients with Leber optic 
atrophy increases the risk of irreversible neurologic damage from the optic 
atrophy due to a reduced ability to detoxify the cyanide intoxication (present in 
tobacco smoke, alcohol, and some plants) (Foulds 1968, Foulds 1969, Foulds 
1970, Wilson and Matthews, 1966). Vitamin B12 is converted to one of two 
cobalamine coenzymes that are active in human metabolism: methylcobalamin 
and 5-deoxyadenosylcobalamin. Within the United States, Vitamin B12 refers to 
cyanocobalamin. The derivatives of vitamin B12 function as cofactor for 
methionine synthase which requires methylcobalamin and L-methylmalonyl-CoA 
mutase which also requires adenosylcobalamine. 
 
L-NAME 
The dosage range for L-NAME is reportedly 2 to 780 mg/kg (Wyse et al., 
2001; Green et al., 1997). Most of the studies of L-NAME have been conductive 
using animal models. There is limited clinical data regarding its use. There is no 
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significant toxicity data available. L-NAME has been noted in animal models to 
attenuate noise induced hearing loss (Diao et al, 2007; Nagashima et al, 2010; 
Rhee, 2003). 
 
Ribose-cysteine  
There are minimal studies within the literature evaluating the toxicity of 
ribose-cysteine. Ribose-cysteine has been noted to be protective against 
acetaminophen induced hepatotoxicity and acetaminophen induced renal toxicity 
(Roberts et al., 1992; Lucas et al., 2000 Slitt et al., 2005). Ribose-cysteine has 
been purported to be effective in the inhibition of astrocytoma cell proliferation 
and effective in the treatment of colitis (Jurkowska et al., 2011; Oz et al., 2007). 
Ribose-cysteine has been reported to be effective within in vitro studies in the 
reduction of the prevalence of radiation-induced mutation and persistent 
chromosomal instability (Waldren et al., 2004). Within animal studies (swine), 
ribose-cysteine has been reported to reduce anastomotic leaks and death 
following rectosigmoid resection and radiation 3 weeks post-operatively (Rowe et 
al., 1993). In each of these studies no adverse effects or toxicities have been 
reported. A dosage ranging of approximately 140 to 3,000 mg/kg has been 
reported in the literature (Kader et al., 2014; Lucas et al., 2000). 
 
L-CySSG 
The literature regarding L-CySSG is scarce regarding toxicity. L-CySS G 
has been reported to be effective in the treatment of colitis (Oz et al., 2007). 
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Preliminary data reveals a trend toward attenuation of age related threshold 
shifts in Fisher 344 rats. L-CySSG has also been found to be protective against 
acetaminophen-induced hepatotoxicity (Berkeley et al., 2003). 
 
 
  
